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INTRODUCTION 
 
 Acute pancreatitis is a disease which has many etiologies. Each 
etiology seems to affect the pancreatic acinar cell in some way that results 
in premature activation and retention of potent proteolytic enzymes 
 In early stages of pancreatitis, macrophages, neutrophils, 
endothelial cells are activated. Preinflammatory cytokines are released 
and inflammation factors re elevated during acute pancreatitis and have 
been implicated in progression of pancreatitis associated microvascular 
disturbance and hemorrhagic necrosis. Ischemia, reperfusion injury and 
tiny thrombosis are closely associated with pancreatic microcirculation 
disturbance1. 
 Severe acute pancreatitis [SAP] is severe and frequently a lethal 
disorder. Its mortality rate reaches upto 25 to 40%.2.SAP is usually 
complicated with systemic inflammatory cascades and microcirculatory 
disturbances – related morbidity due to infected pre pancreatic necrosis. 
 Microcirculation disturbance is a trigger factor and plays an 
important role in the development of multi organ failure.3, 4. Due to high 
mortality rate, search for newer modality of treatment is the hot point in 
the fields of pancreatic surgery. 
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 Low molecular weight heparin (LMWH) is known to posses a 
special anti-thrombin activity which is stronger and safer than 
unfrationated heparin. LMWH can reduce the release of cytokines and 
inflammatory mediators, resulting in an improvement of the 
microcirculation of pancreas. 
 Our experimental study provides evidence that LMWH can block 
the initiation of an inflammatory storm, leading to improvement of 
microcirculation system; and has anti-thrombus effect to reduce the 
formation of microthrombosis in pancreas. These findings demonstrate 
the important therapeutic effect of LMWH in the treatment of acute 
pancreatitis 
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AIM OF THE STUDY 
 
 Effect of LMWH in improvement of microcirculation in acute 
pancreatitis. 
 
OBJECTIVES OF THE STUDY 
 
 To study the effect of low molecular weight heparin (LMWH) in 
the treatment of acute pancreatitis.   
 
 
 
 
 
 
 
 
 
 
 
4  
REVIEW OF LITERATURE 
A. Role Of Low Molecular Weight Heparin In Treatment Of 
Acute Pancreatitis 
 A multiple centre prospective clinical study done to assess the effect 
of Low Molecular Weight Heparin in the treatment of severe acute 
pancreatitis published in 20095 used a total of 265 SAP patients who 
were randomly divided into two groups: firstly, the conventional 
treatment group (C group, n = 130); and secondly the conventional 
treatment plus the LMWH treatment group (LT group, n = 135). The 
clinical parameters, laboratory parameters and computed 
tomography(CT) score of pancreatic necrosis (CTSPN) in the two 
groups were compared.On admission, all the clinical parameters, 
laboratory parameters and CTSPN in the two groups were not 
significantly different (p >0.05). However, after treatment, in LT 
group, the clinical presentation improvement rate and laboratory 
parameters improvement were significantly higher than those in C 
group (p <0.05–0.01), and the acute physiology and chronic health 
evaluation (APACHE) II score, complication rate, mortality and mean 
hospital stay in LT group were obviously lower than those in C group 
(p <0.05–0.01). The CT score in LT group was much lower than that 
in C group (p <0.05). Two weeks after treatment FBI decreased 
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obviously in C group, but not in LT group, and no hemorrhagic 
complications occurred. So, it was concluded that LMWH can 
enhance the effect of conventional treatment for SAP, and can 
markedly decrease the mortality of SAP. LMWH is a simple, safe, 
economic and effective method for treatment of SAP(5). 
 
 A study to explore the clinical effects of low-molecular-weight 
heparin (lmwh) combined with ulinastatin (uti) in children with acute 
pancreatitis6.In total, 560 patients with severe acute pancreatitis 
treated at binzhou people’s hospital, shandong, china, from April 
2012 to June 2014 were enrolled in this study. They were divided into 
control (280 patients, ulinastatin + conventional treatment) and 
observational groups (280 patients, lmwh + ulinastatin + conventional 
treatment). The treatment lasted for 2 weeks. Clinical parameters, 
laboratory test indices, acute physiology and chronic health 
evaluation (apache ii) score, and computed tomography score of 
pancreatic necrosis (ctspn) were assessed in both groups. On 
admission, no significant differences were noted in clinical features, 
laboratory parameters, apache ii scores, or ctspn between the two 
groups (all p > 0.05). After 2 weeks of treatment, serum amylase, 
urine amylase, prothrombin time, fibrinogen, partial thromboplastin 
time, and platelet count in the study group were 913 ± 281 u/l, 1893 ± 
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295 u/l, 16 ± 1.60 s, 3 ± 0.60 g/l, 39.80 ± 5.60 s, and 294 ± 49 × 109/l, 
respectively, all of which were similar or superior to those in the 
control group (1738 ± 346 u/l, 2453 ± 473 u/l, 15 ± 1.50 s, 2.50 ± 
0.50, 39.80 ± 5.90, and 192 ± 37 × 109/l)). Apache ii scores and ctspn 
after 2 weeks of treatment in the observation group were 8.50 ± 1.80 
and 2.10 ± 1, respectively, which were superior to those in the control 
group (9.60 ± 2.40 and 4.30 ± 2.60, respectively; p < 0.05). 
Moreover, the incidence of complications, mortality rate, and average 
duration of the hospital stay in the observation group were lower than 
those in the control group (p > 0.05). The cure rate in the observation 
group was higher than that in the control group. So, it was concluded 
lmwh combined with uti enhances the efficacy of conventional 
treatment and reduces mortality. Thus, it is a potentially effective 
treatment strategy for severe acute pancreatitis in children(6). 
 
 The current study explored the effects of intensive insulin therapy 
(IIT) combined with low molecular weight heparin (LMWH) 
anticoagulant therapy on severe acute pancreatitis (SAP). A total of 
134 patients with SAP that received treatment between June 2008 and 
June 2012 were divided randomly into groups A (control; n=33), B 
(IIT; n=33), C (LMWH; n=34) and D (IIT + LMWH; n=34). Group A 
were treated routinely. Group B received continuous pumped insulin, 
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as well as the routine treatment, to maintain the blood sugar level 
between 4.4 and 6.1 mmol/l. Group C received a subcutaneous 
injection of LMWH every 12 h in addition to the routine treatment. 
Group D received IIT + LMWH and the routine treatment. The white 
blood cell count, hemodiastase, serum albumin, arterial partial 
pressure of oxygen and prothrombin time were recorded prior to 
treatment and 1, 3, 5, 7 and 14 days after the initiation of treatment. 
The intestinal function recovery time, incidence rate of multiple organ 
failure (MOF), length of hospitalization and fatality rates were 
observed. IIT + LMWH noticeably increased the white blood cell 
count, hemodiastase level, serum albumin level and the arterial partial 
pressure of oxygen in the patients with SAP (P<0.05). It markedly 
shortened the intestinal recovery time and the length of stay and 
reduced the incidence rate of MOF, the surgery rate and the fatality 
rate (P<0.05). It did not aggravate the hemorrhagic tendency of SAP 
(P>0.05). IIT + LMWH had a noticeably improved clinical curative 
effect on SAP compared with that of the other treatment(7) 
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Embryology 
 
 The pancreas develops as 2 buds (outpouchings) of endoderm from 
the primitive duodenum at the junction of the foregut and the midgut. 
A small ventral bud (pouch) forms the lower (inferior) part of the 
head and the uncinate process of pancreas, whereas a large dorsal bud 
(pouch) forms the upper (superior) part of the head as well as the 
body and tail of the pancreas. The ventral bud rotates behind the 
duodenum dorsally from right to left and fuses with the dorsal bud, 
and the duct of the distal part (body and tail) of the dorsal bud unites 
with the duct of the ventral bud to form the main pancreatic duct (of 
Wirsung). Because the common bile duct (CBD) also arises from the 
ventral bud, it forms a common channel with the main pancreatic 
duct. The remaining proximal part (head) of the duct of the dorsal bud 
remains as the accessory pancreatic duct (of Santorini). 
9  
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Gross Anatomy 
The pancreas is prismoid in shape and appears triangular in cut section 
with superior, inferior, and anterior borders as well as anterosuperior, 
anteroinferior, and posterior surfaces. 
The head of the pancreas lies in the duodenal C loop in front of the 
inferior vena cava (IVC) and the left renal vein (see the following 
images). The uncinate process is an extension of the lower (inferior)  
half of the head toward the left; it is of varying size and is wedged 
between the superior mesenteric vessels (vein on right, and artery on left) 
in front and the aorta behind it. 
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The lower (terminal) part of the CBD runs behind (or sometimes through) 
the upper half of the head of pancreas before it joins the main pancreatic 
duct (MPD) of Wirsung to form a common channel (ampulla). 
The neck of the pancreas lies in front of the superior mesenteric vein, 
splenic vein and portal vein junction. The body and tail of the pancreas 
run obliquely upward to the left in front of the aorta and left kidney. The 
pancreatic neck is the arbitrary junction between the head and body of the 
pancreas. Portal vein lies behind the neck of the pancreas. The narrow tip 
of the tail of the pancreas reaches the splenic hilum in the splenorenal 
(lienorenal) ligament. 
The pancreatic head constitutes about 50% and the body and tail the 
remaining 50% of the pancreatic parenchymal mass. 
The transverse mesocolon (with the middle colic vessels in it) is attached 
to the anterior surface of the lower (inferior) part of body and tail—most 
of the gland is thus located in the supracolic compartment. The body and 
tail of the pancreas lie in the lesser sac (omental bursa) behind the 
stomach 
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Blood supply 
 
Pancreas derives a rich blood supply from both celiac axis and superior 
mesenteric artery; that is why when angiography is done for bleeding as a 
complication of acute pancreatitis, chronic pancreatitis or 
pancreatoduodenectomy both celiac axis and superior mesenteric artery 
should be evaluated. 
 
The celiac trunk (axis) comes off from the anterior surface of the aorta at 
the level of T12–L1. It has a short length of about 1 cm and trifurcates 
into the common hepatic artery (CHA), splenic artery, and left gastric 
artery (LGA). The CHA runs toward the right on the superior border of 
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the proximal body of the pancreas, and the splenic artery runs toward the 
left on the superior border of the distal body and tail of the pancreas. [1, 
2, 3, 4, 5] 
The superior mesenteric artery (SMA) comes off from the anterior 
surface of the aorta just below the origin of the celiac trunk at the level of 
L1 behind the neck of the pancreas. Then, it descends down in front of 
the uncinate process and the 3rd (horizontal) part of the duodenum to 
enter the small bowel mesentery. 
The gastroduodenal artery (GDA), a branch of the CHA, runs down 
behind the first part of the duodenum in front of the neck of the pancreas 
and divides into the right gastro-omental (gastroepiploic) artery (RGEA) 
and superior pancreaticoduodenal artery (SPDA), which further bifurcates 
into anterior and posterior branches. The inferior pancreaticoduodenal 
artery (IPDA) arises from the SMA and also bifurcates into anterior and 
posterior branches. 
The anterior and posterior branches of the SPDA and IPDA join each 
other and form anterior and posterior pancreaticoduodenal arcades in the 
anterior and posterior pancreaticoduodenal grooves supplying small 
branches to the pancreatic head and uncinate process of the pancreas as 
well as the 1st, 2nd, and 3rd parts of the duodenum (vasa recta duodeni). 
Multiple pancreatic branches (including a great pancreatic artery or 
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arteria magna pancreatica) of the splenic artery supply the pancreatic 
body and tail. Multiple, small pancreatic branches of a dorsal pancreatic 
artery from the splenic artery and an inferior pancreatic artery from the 
superior mesenteric artery supply the body and tail of pancreas. 
The arterial supply of the pancreas forms an important collateral 
circulation between the celiac axis and superior mesenteric artery. 
Veins accompany the SPDA and IPDA. Superior pancreaticoduodenal 
veins (SPDVs) drain into the portal vein and inferior pancreaticoduodenal 
veins (IPDVs) drain into the superior mesenteric vein (SMV). A few 
small, fragile uncinate veins drain directly into the SMV. Some veins 
from the head of the pancreas drain into the gastrocolic trunk. Numerous 
small, fragile veins drain directly from the pancreatic body and tail into 
the splenic vein. 
The SMV lies to the right of the SMA in front of the uncinate process and 
the 3rd part of the duodenum. The splenic vein arises in the splenic hilum 
behind the tail of the pancreas and runs from left to right on the posterior 
surface of the pancreatic body. Union of the horizontal splenic vein and 
the vertical SMV forms the portal vein behind the neck of the pancreas. 
The inferior mesenteric vein (IMV) joins the splenic vein (or the junction 
of the splenic vein and SMV, or even SMV). The portal vein receives the 
15  
SPDVs, right gastro-omental (gastroepiploic vein, left gastric vein 
(LGV), and right gastric vein (RGV); then, it runs up (superiorly) behind 
the first part of the duodenum in the hepatoduodenal ligament behind 
(posterior to) the common bile duct on the right and proper hepatic artery 
on the left. 
The portal venous system (splenic vein, SMV, and portal vein) has no 
valves. 
Lymphatic drainage 
The head of the pancreas drains into pancreaticoduodenal lymph nodes 
and lymph nodes in the hepatoduodenal ligament, as well as prepyloric 
and postpyloric lymph nodes. The pancreatic body and tail drain into 
mesocolic lymph nodes (around the middle colic artery) and lymph nodes 
along the hepatic and splenic arteries. Final drainage occurs into celiac, 
superior mesenteric, and para-aortic and aortocaval lymph nodes. 
Nerve supply 
The pancreas receives parasympathetic nerve fibers from the posterior 
vagal trunk via its celiac branch. Sympathetic supply comes from T6-T10 
via the thoracic splanchnic nerves and the celiac plexus. 
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Natural and Pathophysiologic Variants 
Natural variants 
The main pancreatic duct and common bile duct may not unite to form a 
common channel and open separately at the major duodenal papilla. In 
addition, an aberrant (normal vessel is not present) right hepatic artery 
(RHA) may arise from the superior mesenteric artery (SMA) and 
accessory RHA (in addition to the normal one from common hepatic 
artery [CHA]) from the SMA. 
Pathophysiologic variants 
An annular pancreas is caused by failure of rotation of the ventral bud of 
the pancreas. A ring of pancreas is present around and obstructs the 
second part (C loop) of the duodenum. Neonates with this pancreatic 
variant present with vomiting; abdominal x-rays show a double-bubble 
(gastric and duodenal) appearance. Treatment includes dudodeno-
jejunostomy and not division of the pancreatic ring because it may result 
in pancreatic juice leak and fistula. 
Pancreas divisum is due to failure of the main and accessory pancreatic 
ducts to fuse. In addition to the upper (superior) half of the head of 
pancreas (which it normally also drains), the accessory pancreatic duct 
(of Santorini) also drains the body and tail of pancreas. This drainage 
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may not be adequate (because of the smaller size of the accessory duct) 
and may cause functional obstruction, resulting in recurrent attacks of 
acute pancreatitis. The main pancreatic duct (of Wirsung) drains only the 
lower (inferior) half of the head and uncinate process and does not 
communicate with the accessory duct. 
A long (> 15 mm common channel of pancreatic duct and common bile 
duct is described as anomalous pancreatio biliary ductal junction/ union 
(APBDJ/ APBDU) - it is associated with choledochal cyst and carries a 
higher risk of biliary malignancy.  
Accessory pancreatic tissue may be present in the stomach, small 
intestine, Meckel diverticulum, omentum, and hilum of spleen as soft 
yellow nodules/lobules. 
Physiology  
Pancreas is one of the organs in the body that has both exocrine and 
endocrinal functions. The function of the pancreas is to make digestive 
enzymes which digest food materials in the small intestines. In addition 
the pancreas also makes insulin which controls the blood glucose levels. 
Exocrine Function 
The adult pancreas produces 10 -20g of pancreatic enzymes in an active 
form.It secretes a colorless odorless alkaline (pH 7.6-9) juice with 
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enzymes such as – amylase, lipase, proteases and trypsinogen which help 
digest the fat, protein as well as carbohydrates from the food that we eat. 
The alkaline juice helps to neutralize the acid secretions of the stomach. It 
secretes about 1.5 liters of these juices in a day. The stimulants for 
enzymes secretion are secretin, cholecystokinin and acetylcholine. 
The enzymes are conveyed to the upper part of the small intestine called 
duodenum via a tube called the pancreatic duct. 
Endocrine Function 
It also secretes two important hormones namely – Insulin and Glucagon 
which are essential for regulation of glucose in the blood. Insulin is 
synthesizes by the B cells. Proinsulin is transported from the endoplasmic 
reticulum to the Golgi complex where it is packaged into granules and 
cleaved into insulin and residual connective peptide (C peptide). 
Glycogen is secreted by the A cells of the islet. It elevates blood glucose 
levels through the stimulation of glycogenolysis and gluconeogenesis. Its 
major stimulants are aminoacids and cholinergic fibers. Somatostatin is 
secreted by the D cells of the islet. It inhibits the release of growth 
hormone and almost all peptide hormones. It also inhibits gastric, 
pancreatic and biliary secretion. 
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B. Definition of acute pancreatitis 
 The International Symposium on Acute Pancreatitis (Atlanta, 
September 1992) defined Acute Pancreatitis as “An acute inflammatory 
process of the pancreas, with variable involvement of other regional 
tissues or remote organ systems” (8) 
 Acute Pancreatitis is an inflammatory disease of the pancreas that 
is associated with little or no fibrosis of the gland and by definition, it is 
reversible. It is distinguished from chronic pancreatitis by the absence 
of continuing inflammation, irreversible structural changes and 
permanent impairment of exocrine and endocrine pancreatic function. 
Acute pancreatitis can be initiated by several factors, including 
gallstones, alcohol, trauma and infections and in some cases, it is 
hereditary. Very often patients with acute pancreatitis develop 
additional complications such as sepsis, shock, respiratory and renal 
failure, resulting in considerable mortality and morbidity. 
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C. Classification of Acute Pancreatitis 
 A commonly used classification system (the Atlanta classification) 
(8) divides AP into two broad categories. The classification was 
developed following 3 days of group meetings and open discussions, 
with unanimous consensus on a series of definitions for a clinically 
based classification system for acute pancreatitis by a diverse group of 
40 international authorities from six medical disciplines and 15 
countries. The proposed classification system was to be of value to 
practicing clinicians in the care of individual patients and to 
academicians seeking to compare inter-institutional data.  
The Atlanta Classification: 
(1) Mild : (edematous and interstitial) acute pancreatitis 
(2) Severe: (usually synonymous with necrotizing) acute pancreatitis 
The criteria for severe AP included any of the following: 
1) A Ranson’s score of 3 or more 
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2) An APACHE II score of 8 or more within the first 48 hours 
3) Organ failure (respiratory, circulatory, renal, and/or GI bleeding) 
4) Local complications (pancreatic necrosis, abscess or pseudocyst) 
 
Most attacks of AP are mild with recovery occurring within five to 
seven days. Death is unusual (less than 3 percent) in such patients. (9) 
 Approximately 15 to 25 percent of all cases are severe. Severe 
necrotizing pancreatitis is associated with a high rate of complications 
(local and systemic) and mortality (approximately 17%) 
Severe Acute Pancreatitis as defined by Atlanta Symposium: 
 Early prognostic signs 
 Ranson’s score >3 
 APACHE II score >8 
 Organ failure and/or Local complications 
 Necrosis  
 Abscess 
 Pseudocyst 
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 However some patients with local complications in the absence of 
organ failure are seen to have low mortality rates, like patients with mild 
acute pancreatitis, but have prolonged hospitalizations, like patients with 
severe acute pancreatitis in a new subgroup called “moderately severe 
acute pancreatitis”(10) 
The Atlanta classification has several deficiencies(11) : 
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 It fails to recognize multiple and persistent (> 48 hours) organ 
failure, which is more predictive of severity than transient organ 
failure. 
 The nomenclature developed to describe local complications 
cannot be used to describe findings such as walled off pancreatic 
necrosis and does not allow for the differentiation of infected from 
sterile necrosis 
 It combines predicting systems (early) and local complications 
(late) to define severe acute pancreatitis. 
 
Revised Atlanta Classification: 
 The Revised Atlanta Classification was initiated as an 
international, web-based process that began in a clinical symposium in 
2007 at the Digestive Diseases Week (12). 
Revision of the Atlanta classification was made with an intent to address 
areas of confusion in the original Atlanta Classification, incorporate 
modern concepts of the disease, improve clinical assessment of severity, 
enable standardized data reporting, assist objective evaluation of new 
treatments, and facilitate communication among treating physicians and 
different institutions. 
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Components 
The Revised Atlanta Classification dealt primarily with two broad areas, 
namely,  
a) discrete definitions of organ failure and local complications 
(including necrosis)  and  
b) classification of severity of the disease. 
 The revised classification categorizes AP into interstitial 
edematous (IEP) and necrotizing pancreatitis based on contrast enhanced 
computed tomography (CECT) imaging. IEP constitutes 80-90% of AP, 
in which the pancreas appears relatively homogenously enhanced on 
CECT with or without mild peripancreatic stranding or peripancreatic 
fluid collection. Necrotizing pancreatitis on the other hand is 
characterized by lack of enhancement of the pancreas and/or (peri) 
pancreatic tissues on CECT. Both the pancreatic parenchyma and 
peripancreatic tissues together are involved more frequently than 
involvement of either alone. Recognition of the degree of necrosis 
(pancreatic alone, peripancreatic alone, or both) is important since the 
prognosis varies. 
 According to the Revised Atlanta Classification, complications of 
AP can be: organ failure, local and systemic complications. 
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 Organ failure may be transient (resolves within 48 h of onset) or 
persistent (persists for 48 h and more). Local complications include fluid 
collections, gastric outlet dysfunction, splenic and portal vein thrombosis, 
and colonic necrosis. Four discrete types of collections have been 
described, namely, acute peripancreatic fluid collection (APFC), 
pancreatic pseudocyst (PP), acute necrotic collection (ANC) and walled 
off necrosis (WON). 
Sentinel Loop Sign 
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Colon Cutoff Sign 
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Determinant based classification: 
 The primary highlight of the Determinant Based Classification was 
the introduction of the group called critical AP. This category and thereby 
the Determinant Based Classification stemmed from the results of a meta-
analysis of 14 studies involving 1478 patients that evaluated the pooled 
effect of organ failure and infected pancreatic necrosis on mortality (13). 
The meta-analysis demonstrated that mortality rate among patients who 
had both organ failure and infected pancreatic necrosis was 43%. 
28  
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Determinants  
 The Determinant Based Classification primarily centers on causally 
associated factors (or determinants) for mortality. The determinants could 
be  
1) local, i.e. (peri)pancreatic necrosis or  
2) systemic, i.e. organ failure.  
 (Peri) pancreatic necrosis is defined as nonviable tissue located in 
the pancreas alone, or in the pancreas and peripancreatic tissues, or in the 
peripancreatic tissues alone. (Peri) pancreatic necrosis could be sterile or 
infected. Infected (peri) pancreatic necrosis is defined by the presences of 
either gas bubbles within necrotic areas on computed tomography, a 
positive culture of (peri) pancreatic necrosis obtained by image guided 
fine-needle aspiration, or positive culture of (peri) pancreatic necrosis 
obtained during the first drainage and/or necrosetomy. Organ failure is 
defined as a score of 2 or more according the Sequential Organ Failure 
Assessment (SOFA) system (14) ; or if there is a need for inotropic support 
and/or serum creatinine of > 2 mg/dl, and/or PaO2/FiO2 < 300 mm Hg. 
Organ failure for 48 h or more is defined as persistent, while it is defined 
as transient if less than 48 h. 
The four categories in the Determinant Based Classification include: 
1) mild - absence of both (peri) pancreatic necrosis and organ failure 
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2) moderate - sterile (peri) pancreatic necrosis and/or transient organ 
failure 
3) severe - presence of either infected (peri) pancreatic necrosis or 
persistent organ failure 
4) critical AP - presence of both infected (peri) pancreatic necrosis 
and persistent organ failure.  
CT – Image Acute Necrotising Pancreatitis 
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D. Etiology of Acute Pancreatitis : 
 Acute Pancreatitis is an inflammatory condition of the pancreas 
characterized clinically by abdominal pain and elevated levels of 
pancreatic enzymes in the blood. (15,16) In mild AP, the pancreas recovers 
its normal endocrine and exocrine functions and histology. Patients with 
severe acute pancreatitis develop permanent endocrine and exocrine 
insufficiencies depending on the extent of pancreatic injury and necrosis, 
irrespective of the etiology. Scarring of the pancreatic ducts can persists 
in some patients, mimicking the ductal changes of chronic pancreatitis. 
(17) 
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The complex pathogenesis of AP is still not very clearly 
understood, although several theories based on animal model studies have 
been put forward. A number of conditions are suspected, with varying 
degrees of certainty, to induce acute pancreatitis. Gallstones and chronic 
alcohol abuse accounts for 75-80% of the cases, the rest are attributed to 
other factors such as Hypertriglyceridemia, Hypercalcemia, drugs, 
smoking, genetic mutations, infection, trauma, factors causing ampullary 
obstruction etc. A minor subset of patients have no identifiable etiology, 
and the cause of pancreatitis remains undetermined. As our knowledge 
and understanding of the disease grows, the number of so called 
“idiopathic” cases will decrease as our list of causes grows. 
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 A review on the epidemiology of acute pancreatitis found an 
increasing incidence (especially that due to alcohol and gallstones in 
some areas) and decreasing case-fatality rate(18) 
Gallstones and other causes of mechanical ampullary obstruction: 
 Mechanical ampullary obstruction can be induced by gallstones 
and a variety of disorders. The most common cause of acute pancreatitis 
in most areas of the world is gallstones (including microlithiasis), which 
accounts for 35 to 40 % of cases.(19) Cholecystectomy and clearing the 
common bile duct of stones prevents recurrence, confirming the cause 
and effect relationship. (20) 
The mechanism by which the passage of gallstones induces pancreatitis is 
unknown. Two factors have been suggested as the possible initiating 
event in gallstones pancreatitis: 
a) Reflux of bile into the pancreatic duct due to transient obstruction 
of the ampulla during passage of gallstones(21) 
b) Obstruction at the ampulla secondary to stones or edema resulting 
from the passage of gallstones(22) 
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Gallstone Ultra sonogram 
 
Incidence of gallstones (biliary pancreatitis): 
 Although 35 percent of attacks of Acute Pancreatitis are caused by 
gallstones, only 3 to 7 % of patients with gallstones eventually develop 
pancreatitis. (20,23) Gender and stone size may be risk factors for gallstone 
pancreatitis. The risk of developing AP in patients with gallstones is 
greater in men; however, more women develop this disorder since 
gallstones occur with increased frequency in women.  
 It has been suggested that acute pancreatitis is associated with a 
stone diameter of less than 5mm and that smaller stones or microlithiasis 
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are more likely than larger stones to pass through the cystic duct and 
cause obstruction at the ampulla. (24,25) 
 
Management of Biliary Pancreatitis  
 The diagnosis of gallstones pancreatitis should be suspected if the 
patient has a prior history of biliary colic. In addition all patients with a 
first attack of acute pancreatitis should have an abdominal ultrasound to 
search for gallstones, common bile duct stones or signs of extrahepatic 
biliary tract obstruction. (23)  Laboratory values obtained during the acute 
attack may also assist in making the diagnosis. Serum alanine 
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aminotransferase (ALT) concentration is the most clinically useful 
parameter in predicting a gallstone etiology in patients with acute 
pancreatitis. (26) 
 If gallstone pancreatitis is suspected on the basis of imaging and 
laboratory findings and there is no history of alcohol abuse, 
cholecystectomy with cholangiography is recommended during the same 
hospitalization. ERCP is performed after laproscopic cholecystectomy if 
a common bile duct stone is found and not removed at surgery. 
Biliary sludge and Microlithiasis 
 Biliary sludge is a viscous suspension in the gallbladder bile that 
may contain small stones (<5 mm in diameter). It is formed by 
modification of hepatic bile by gallbladder mucosa; thus hepatic bile 
samples may be insufficient for its diagnosis.(27) 
 Most patients with biliary sludge are asymptomatic. (27) Sludge 
appears as a mobile, low- amplitude echo on ultrasound that layers in the 
most dependent part of the gallbladder and is not associated with 
shadowing. Microscopic analysis of bile in patients with sludge often 
shows cholesterol monohydrate crystals or calcium bilirubinate granules. 
(28) 
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 Sludge is typically found in patients with functional or mechanical 
bile stasis, such as those undergoing a prolonged fast, with distal bile duct 
obstruction, or on total parenteral nutrition. In addition, certain drugs that 
excreted by hepatocytes, such as ceftriaxone, can complex with bile to 
form sludge within the biliary system when its solubility in bile is 
exceeded. 
 Biliary sludge is commonly found in patients with acute 
pancreatitis with no obvious cause. However, the association between 
biliary sludge and acute pancreatitis is unproven. Because of the high risk 
of recurrence, cholecystectomy is recommended in patients who have had 
an episode of pancreatitis and have biliary sludge.(29) 
Other causes of Acute Pancreatitis secondary to Ampullary 
Obstruction 
 Other conditions causing obstruction of the ampulla that have been 
associated with pancreatitis include biliary ascariasis, periampullary 
diverticula and pancreatic and periampullarytumours. Intraductal 
papillary mucinous neoplasms (IPMN) of the pancreas are being 
recognized increasingly and may occasionally present as acute 
pancreatitis, especially in elderly nonalcoholic males. 
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Alcohol and Acute Pancreatitis 
 Acute alcoholic pancreatitis, along with gallstones pancreatitis, is 
the most common diagnosis among patients hospitalized with pancreatic 
disease.(30-34) Approximately  10 % of chronic alcoholics develop attacks 
of clinically acute pancreatitis. Studies have shown that not all patients 
progress to chronic pancreatitis, even with continued alcohol abuse. (35) 
 Why only a small proportion of all alcoholics develop pancreatitis, 
what genetic and environmental factors influence the development of 
pancreatitis in alcoholics, and what is the exact mechanism of pancreatic 
injury by alcohol remain unanswered in spite of extensive and ongoing 
research. 
Role of smoking in the etiology of Acute Pancreatitis 
 Until recently, smoking was thought to be a risk factor due to its 
association with alcohol. However, at least three large studies have 
suggested that cigarette smoking is an independent risk factor for acute 
pancreatitis by mechanisms that are unclear. (36,37,38) 
Hypertriglyceridemia 
 Serum triglyceride concentrations above 1000 mg/dL can 
precipitate attacks of acute pancreatitis, although the pathogenesis of 
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inflammation in this setting is unclear.(39) Hypertriglyceridemia may 
account for 1.3  to 3.8 percent of cases of acute pancreatitis. (40) 
 Hypertriglyceridemia, with concentrations severe enough to trigger 
attacks of acute pancreatitis, may even be present in children as a part of 
a spectrum of inherited lipoprotein metabolism disorders. Acquired 
causes of hypertriglyceridemia include obesity, diabetes mellitus, 
hypothyroidism, pregnancy, estrogen or tamoxifen therapy, 
glucocorticoid excess, nephrotic syndrome and beta blockers. 
Hypercalcemia 
 Hypercalcemia of any cause can lead to acute pancreatitis, although 
actual incidence is low. Proposed mechanisms include deposition of 
calcium in the pancreatic duct and calcium activation of trypsinogen 
within the pancreatic parenchyma. (41) 
Genetic mutations 
 There have been tremendous advances in the past few years in our 
understanding of the genetic basis of acute pancreatitis. Some genetic 
disorders are associated with a high-penetrance (eg, mutations at codons 
29 and 122 of the serine protease I (cationic trypsinogen) gene (PRSS1), 
while others have a low penetrance and are more frequent in the general 
population (eg, mutations in the serine protease inhibitor Kazal type I 
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(SPINK1), which may act as a disease modifier). In addition, certain 
mutations in the cystic fibrosis gene (CFTR) have been associated with 
acute pancreatitis. 
 Inherited forms of pancreatitis, which may present as recurrent 
acute pancreatitis but eventually progresses to chronic pancreatitis, may 
be inherited as autosomal dominant, autosomal recessive or be a 
mutagenic disorder as a result of mutations in these or yet unidentified 
genes. 
Drug induced Acute Pancreatitis 
 Acute pancreatitis related to drug or medication use is uncommon. 
The literature on drug-induced pancreatitis mostly consists of case reports 
and anecdotal account. Many drugs have been implicated as etiologic 
agents, and the list continues to grow. (42) 
 The following drugs were definitely associated with pancreatitis by 
at least two of the three reviews of this subject (42):     
 AIDS therapy-didanosine, pentamidine 
 Antimicrobial agents-metronidazole, stibogluconate, sulfonamides, 
tetracycline 
 Diuretics-furosemide, thiazides 
 Drugs used for inflammatory bowel disease-sulfasalazine, 5-ASA 
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 Immunosuppressive agents –L-asparaginase, azathioprine 
 Neuropsychiatric agents-valporic acid 
 Anti-inflammatory drugs-sulindac, salicylates 
 Others-calcium, estrogen,tamoxifen 
 
 The pathogenesis of drug-induced pancreatitis may be due to an 
idiosyncratic response in some cases (eg, 6-mercaptopurine, 
aminosalicylates, and sulfonamides) or due to a direct toxic effect (eg, 
diuretics, sulfonamides). 
 A high index of suspicion and careful drug history are essential for 
making the diagnosis. The time course of developing the disorder 
depends upon the drug involved. 
Infectious causes of Acute Pancreatitis 
 There are numerous case reports of acute pancreatitis due to a wide 
variety of infectious agents.  
Cases of definite pancreatitis were associated with the following 
organisms(43): 
 Viruses–mumps, Coxsackie virus, Hepatitis B, Cytomegalo virus, 
Varicella-zoster, Herpes simplex 
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 Bacteria-Mycoplasma, legionella, Leptospira, Salmonella 
 Fungi-Aspergillus 
 Parasites-Toxoplasma, Cryptosporidium, Ascaris 
The frequency with which these infections lead to pancreatitis is not 
known. 
Trauma 
 Blunt or penetrating trauma can damage the pancreas and cause 
acute pancreatitis, although these injuries are uncommon due to the 
retroperitoneal location of the gland. The diagnosis of traumatic 
pancreatitis is difficult and requires a high degree of suspicion. 
Vascular disease 
 Pancreatic ischemia is an uncommon cause of clinically significant 
pancreatitis. However, ischemia with resultant pancreatitis has been 
reported in the following circumstances(45): 
 Vasculitis (SLE and PAN) 
 Atheroembolism 
 Intraoperative hypotension 
 Hemorrhagic shock 
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Acute Pancreatitis Post-ERCP 
 Asymptomatic hyperamylasemia occurs in 35 to 70 percent of 
patients undergoing ERCP. A diagnosis of post-ERCP pancreatitis is 
generally made if the hyperamylasemia is accompanied by persistent 
severe upper abdominal pain, often with nausea and vomiting. Acute 
pancreatitis occurs in about 3 % of patients undergoing diagnostic ERCP, 
5% of patients undergoing therapeutic ERCP, and up to 25 % undergoing 
sphincter of Oddimanometric studies. (46) 
Idiopathic Acute Pancreatitis 
 No obvious etiology is identifiable [history (e.g., alcohol, family 
history), laboratory tests (e.g., gallstone pancreatitis, hyperlipidemia, 
hypercalcemia), and abdominal ultrasound] in up to 30 % of patients with 
acute pancreatitis. The term idiopathic pancreatitis is used for these who 
have no cause found even after an exhaustive search for an etiology. Most 
recommendations suggest that extensive investigation for unusual cause 
of pancreatitis is not required after the first episode of unexplained 
pancreatitis. Approximately 15 to 25 % of patients with acute pancreatitis 
may be labelled as idiopathic and this figure will probably decrease in the 
future with better identification of different causes.   
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E. Pathogenesis of acute pancreatitis: 
 Acute pancreatitis is an inflammatory condition of the pancreas 
characterized clinically by abdominal pain and elevated levels of 
pancreatic enzymes in the blood. The disease process can be localized or 
affect the whole pancreas, and is a disease with typically unpredictable 
course.(47)  A number of conditions known to induce this disorder. The 
exact mechanisms by which diverse etiological factors induce an attack 
are still unclear. It is generally believed that the earliest events in acute 
pancreatitis occur within acinar cells. Acinar cell injury early in acute 
pancreatitis leads to a local inflammatory reaction. If this inflammatory 
reaction is marked, it leads to a systemic inflammatory response 
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syndrome (SIRS). An excessive SIRS leads to distant organ damage and 
multiple organ dysfunction syndrome (MODS).MODS associated with 
acute pancreatitis is the primary cause of morbidity and mortality in this 
condition. (48) 
Animal Models Demonstrate Pathogenesis of Inflammatory Response 
 Although a number of animal models have been developed to 
understand the pathogenesis of acute pancreatitis, none is strictly 
comparable to the human condition.(49) Alcohol abuse and gall stones are 
implicated in the etiopathogenesis of 90% of cases of acute pancreatitis in 
India (50) which is comparable to their role stated in western literature. 
(33,34,51-53) 
 However, none of the existing animal models duplicates these 
situations. In addition, the commonly used agents for inducing 
pancreatitis in animal models, such as cerulin and a choline-deficient 
ethionine-supplemented diet, are not recognized causes of human acute 
pancreatitis. (49) 
 Nevertheless, the structural and biochemical changes seen in early 
phases of acute pancreatitis are remarkably constant in different animal 
models, and similar changes have been demonstrated in human acute 
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pancreatitis. Furthermore, the clinical and pathologic features of human 
acute pancreatitis, regardless of the inciting event, are very similar.(49,50,51) 
    Despite the limitations of animal models, the data suggest that a similar 
cascade of events occurs once pancreatitis begins independent of the 
inciting event or initial mechanism. (50) Animal studies have shown that 
this cascade cannot be halted successfully unless therapy is initiated 
either prophylactically or within a few hours of the initiating event. It is 
not clear from these studies why some individuals develop interstitial or 
edematous pancreatitis, while others go on to develop the necrotizing 
form of the disease. (52) 
 Thus animal models help us understand the mechanisms and 
subsequent consequences of intra-pancreatic digestive enzyme activation, 
the generation and role of cytokines and other inflammatory mediators in 
the pancreatic acinar cell, and the role of extra-acinar players such as 
inflammatory cells in pancreatic inflammation. Further, mechanistic 
advances have also been made in understanding the modes of cell death, 
including apoptosis and necrosis, and their relevance to pancreatitis. 
 From these experimental studies, numerous factors have been 
implicated in causing pancreatic injury, including intra-pancreatic 
digestive enzyme activation (53), cytokines and chemokines(54), 
inflammatory cells (55), peptide mediators such as substance P (56), small 
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molecule mediators such as nitric oxide (57), reactive oxygen species (43), 
polyamine depletion (58), and cyclooxygenase (COX) – 2 (59). While 
pancreatitis may be due to several of these factors acting in different 
ways, the disease frequently develops in severity over time and thus it is 
important to understand the initial events that trigger or exacerbate it, so 
as to design treatments that are beneficial if administered in the early 
stages of presentation. 
Triggering event: 
 Only a small percent of people with predisposing factors actually 
develop acute pancreatitis. For example, several large population based 
studies have drawn the conclusion that only 3-7 % with gallstones, 10% 
of alcoholics and <1% of patients with hypercalcemia eventually contract 
pancreatitis. (60) 
 The exact mechanism of induction of acute pancreatitis is not 
known. However several theories have been put forward. 
 In alcohol induced acute pancreatitis ongoing studies are being 
conducted to elucidate the following possible triggering pathways (30): 
1) sensitization of acinar cells to CCK by the activation of zymogens 
2) Potentiation of the effect of CCK on the activation of transcription 
factors, nuclear factor kB, and activating protein – 1 
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3) Generation of toxic metabolites such as acetaldehyde and fatty acid 
ethyl esters 
4) Sensitization of the pancreas to the toxic effects of coxsackie virus 
B3  
5) Activation of pancreatic stellate cells by acetaldehyde and 
oxidative stress and subsequent increased production of collagen 
and other matrix proteins. 
Two factors have been suggested as the possible initiating events   
in gallstones pancreatitis:  
1) reflux of bile into the pancreatic duct due to transient obstruction of 
the ampulla during passage of gallstones 
2) obstruction at the ampulla secondary to stone(s) or edema resulting 
from the passage of a stone 
In hyperlipidemia it has been suggested that the triggering factor is 
free fatty acids that are released from serum triglycerides in toxic 
concentrations by the action of pancreatic lipase within pancreatic 
capillaries. (39) 
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Early Acute Changes 
Intra-acinar activation of proteolytic enzymes: 
 One of the earliest events seen in different models of acute 
pancreatitis is blockade of secretion of pancreatic enzymes while 
synthesis continues. 
 The central requirement for induction of acute pancreatitis is 
intraacinar activation of these proteolytic enzymes, which ultimately 
leads to autodigestive injury to the gland. 
 A proposed mechanism by which intra-acinar activation occurs and 
leads to pancreatic destruction in animal models of pancreatitis is as 
follows: (60) 
1) a devastating event occurs very early which allows generation of 
large amounts of active trypsin within the pancreas. 
2) Collection of lysosomal enzymes such as cathepsin B and digestive 
vacuoles within the acinar cell/ in the normal acinar cell, these two 
groups of enzymes are carefully sorted by the Golgi network. 
3) In early pancreatitis, however, cathepsin B cleaves the trypsinogen 
activation peptide from trypsinogen within the acinar vacuoles, 
leading to intra pancreatic activation of trypsin. 
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4) The normal defense mechanisms of the pancreas are overwhelmed 
by the large amounts of trypsin released. 
5) The intra pancreatic release of trypsin leads to activation of more 
trypsin, and other pancreatic enzymes such as phospholipase, 
chymotrypsin, and elastase. 
6) Trypsin also activates other enzymes cascades including 
complement, kallikrein- kinin, coagulation and fibrinolysis. 
7) The intra pancreatic release of active pancreatic enzymes leads to 
pancreatic autodigestion 
 This sets up a vicious cycle of active enzymes damaging cells, 
which then release more active enzymes. The destruction spreads along 
the gland and into the peripancreatic tissue. 
Microcirculation injury: 
 The release of pancreatic enzymes damage the vascular 
endothelium and the interstitium as well as the acinar cells. 
Microcirculatory changes, including vasoconstriction, capillary  stasis, 
decreased oxygen saturation and progressive ischemia, occur early in 
experimental models of acute pancreatitis. These changes lead to 
increased vascular permeability and swelling of the gland (edematous or 
interstitial pancreatitis). Vascular injury could lead to local 
microcirculatory failure and amplification of the pancreatic injury. (45, 61) 
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 There is also speculation about the role of ischemia- reperfusion 
injury in the pancreas. Reperfusion of damaged tissues leads to the 
release of free radicals and inflammatory cytokines into the circulation, 
which could cause further injury.(61) The importance of microcirculatory 
injury can be appreciated by the importance of aggressive fluid 
replacement in the management of acute pancreatitis, which minimizes 
this injury.          
Leucocyte chemoattraction and release of cytokines 
 Microscopic and radionuclide studies using Indium – 111 tagged 
leukocytes show marked glandular invasion by macrophages and 
polymorphonuclear leukocytes in early stages of animal and human 
pancreatitis. Activation of complement and the subsequent release of C5a 
have a significant role in the recruitment of these inflammatory cells. 
 Granulocyte and macrophage activation causes the release of 
proinflammatory cytokines (tumor necrosis factor, interleukins 1,6 and 
8), arachidonic acid metabolites (prostaglandins, platelet-activating 
factor, and leukotrienes), proteolytic and lipolytic enzymes, and reactive 
oxygen metabolites which overwhelm the scavenging capacity of 
endogenous antioxidant systems. These substances also interact with the 
pancreatic microcirculation to increase vascular permeability and induce 
thrombosis and hemorrhage, leading to pancreatic necrosis. 
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 Activated pancreatic enzymes, microcirculatory impairment, and 
the release of inflammatory mediators lead to rapid worsening of 
pancreatic damage and necrosis. This interaction makes it difficult to 
estimate the individual roles of these factors in inducing pancreatic 
damage. In addition, approximately 80 percent with pancreatitis develop 
only interstitial pancreatitis rather than necrotizing pancreatitis; the 
factors involved in limiting the pancreatic damage are not well 
understood. 
Systemic Response 
 Some patients with severe pancreatic damage develop systemic 
complications including fever, acute respiratory distress syndrome 
(ARDS), pleural effusions, renal failure, shock, and myocardial 
depression. 
 This systemic inflammatory response syndrome (SIRS) is probably 
mediated by activated pancreatic enzymes (phospholipase, elastase, 
trypsin, etc) and cytokines (tumor necrosis factor, platelet activating 
factor) released into the circulation from the inflamed pancreas. 
 ARDS, in addition to being secondary to microvascular 
thrombosis, may be induced by active phospholipase A ( lecithinase), 
which digests lecithin, a major component of surfactant. Myocardial 
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depression and shock are thought to be secondary to vasoactive peptides 
and a myocardial depressant factor. Acute renal failure has been 
explained on the basis of hypovolemia and hypotension. Metabolic 
complications include hypocalcemia, hyperlipidemia, hyperglycemia, 
hypoglycemia, and diabetic ketoacidosis. The pathogenesis of 
hypocalcemia is multifactorial and includes calcium- soap formation, 
hormonal imbalances (eg, pararthyroid hormone, calcitonin, glucagon), 
binding of calcium by free fatty acid-albumin complexes, and 
intracellular translocation of calcium. 
 These systemic complications are uncommon and much less severe 
in patients with interstitial pancreatitis than in those with necrotizing 
pancreatitis. However, only about 50 percent of patients with necrotizing 
pancreatitis develop organ failure, and this complication cannot be 
predicted from the degree of pancreatic necrosis. One study suggested 
that an increased tissue concentration of macrophage migratory inhibitory 
factor was a critical factor in the pathogenesis of severe acute 
pancreatitis. 
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Acute Respiratory Distress syndrome 
 
 Bacterial translocation – The normal human gut prevents the 
translocation of bacteria into the systemic circulation through a complex 
barrier that consists of immunologic, bacteriologic, and morphologic 
components. During the course of acute pancreatitis, the gut barrier is 
compromised, leading to translocation of bacteria, which can result in 
local and systemic infection. The breakdown in the gut barrier is thought 
to be a consequence of ischemia due to hypovolemia and pancreatitis- 
induced gut arteriovenous shunting. 
 Most infections in acute pancreatitis are caused by common enteric 
organisms suggesting that they originate from the gastrointestinal tract. 
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 The consequences of bacterial translocation the gut in acute 
pancreatitis can be lethal. Local bacterial infection of pancreatic and 
peripancreatic tissues occurs in approximately 30 percent of patients with 
severe acute pancreatitis, potentially resulting in multiorgan failure and 
its sequelae. 
The Inflammatory Cascade in Acute Pancreatitis: 
Triggering events: 
 A number of situations can precipitate acute pancreatitis in 
humans, but only a small fraction of patients with these predisposing 
factors ultimately develop the disease. For example, only 3 to 7 percent of 
people with gallstones (23); 10 percent of alcoholics; and a few patients 
with hypercalcemia(60) eventually develop acute pancreatitis. 
Alcoholic Pancreatitis 
 The exact mechanism of induction of pancreatitis by these agents 
in not known. It is unclear, for example, why alcohol- induced 
pancreatitis occurs only after manyyears of alcohol abuse and not after a 
single binge in humans not habituated to alcohol use. However, several 
mechanisms have been proposed for the development of acute 
pancreatitis in alcoholics:(30) 
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1) Sensitization of acinar cells to CCK – induced premature activation 
of zymogens 
2) Potentiation of the effect of CCK on the activation of transcription 
factor, nuclear factor kB, and activating protein – 1 
3) Generation of toxic metabolites such as acetaldehyde and fatty acid 
ethyl esters 
4) Sensitization of the pancreas to the toxic effects of coxsackie virus 
B3 
5) Activation of pancreatic stellate cells by acetaldehyde and 
oxidative stress and subsequent increased production of collagen 
and other matrix proteins. 
Different mechanisms have been proposed for other forms of pancreatitis. 
Gallstones Pancreatitis 
1) reflux of bile into the pancreatic duct due to transient obstruction of 
the ampulla during passage of gallstones (47) 
2) obstruction at the ampulla secondary to stone(s) or edema resulting 
from the passage of a stone (48) 
3) Another defense mechanism involves mesotrypsin and enzyme Y, 
which lyses and inactivates trypsin. 
4) non specific antiproteases such as alpha – 1 antitrypsin and alpha – 
2 macroglobulin are present in the pancreatic interstitium. 
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 To summarize, cationic trypsin is the most abundant form of 
trypsin produced by the pancreas and is the primary catalyst for the 
conversion of pancreatic zymogens into pancreatic digestive enzymes 
after they are secreted into the duodenum. Premature activation of 
digestive enzymes in the pancreas is the major cause of pancreatic injury 
and immune system activation, leading to acute pancreatitis and later 
chronic pancreatitis. The primary defense against pancreatitis is to control 
trypsin activity, either through prevention of premature activation of 
trypsinogen to trypsin, or by the destruction, inhibition, or elimination of 
trypsin from the pancreas. (63) 
Intra- acinar activation of proteolytic enzymes 
 One of the earliest events in the different models of acute 
pancreatitis is blockade of secretion of pancreatic enzymes while 
synthesis continues.(90) It is becoming increasingly clear that the central 
event in the triggering of acute pancreatitis is the activation of these 
proteolytic enzymes within the acinar cells of the gland leading to auto 
digestive injury of pancreatic tissue 
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Proposed cascade of events in Intra-acinar activation of proteolytic 
enzymes: 
 Co localization of lysosomal enzymes, such as cathepsin B and 
digestive enzymes including trypsinogen, occurs in unstable 
vacuoles within the acinar cell (64). In the normal acinar cell, the 
golgi network carefully sorts these two groups of enzymes. In early 
pancreatitis, however, cathepsin B cleaves the trypsinogen 
activation peptide from trypsinogen within the acinar vacuoles, 
leading to intrahepatic activation of trypsin (64) 
 The normal defense mechanisms of the pancreas are overwhelmed 
by the large amounts of trypsin released. In addition, the 
intrapancreatic release of trypsin leads to activation of more 
trypsin, and other pancreatic enzymes such as phospholipase, 
chymotrypsin, and elastase. Trypsin also activates other enzyme 
cascades including complement, kallikrein – kinin, coagulation and 
fibrinolysis. (29) 
 The intrapancreatic release of active pancreatic enzymes leads to 
pancreatic autodigestion, setting up a vicious cycle of active 
enzymes damaging cells, which then release more enzymes. The 
destruction spreads along the gland into the peripancreatictissue(65) 
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       The activation of trypsinogen occurs before either biochemical or 
morphological injury to acinar cell is evident. 
 An in vitro model found that complete inhibition of pancreatic 
cathepsin B activity with E-644(a specific potent and irreversible 
cathepsin B inhibitor) prevented cerulean-induced trypsinogen 
activation(66) 
 This observation supports the significance of cathepsin B 
activation of trypsinogen, and the importance of co-localization of 
pancreatic digestive enzymes and lysosomal hydrolases. In addition, it 
suggest that complete inhibition of cathepsin B may be of benefit in either 
the prevention or treatment of acute pancreatitis 
 Other mechanism besides cathepsin B have also been suggested to 
have a role like trypsinogenautoactivation or activation by other 
lysosomal proteinases 
Microcirculation injury: 
The release of pancreatic enzymes damage the vascular endothelium and 
the interstitium as well as the acinar cells. Microcirculatory changes, 
including vasoconstriction, capillary  stasis, decreased oxygen saturation 
,and progressive ischemia, occur early in experimental models of acute 
pancreatitis. These changes lead to increased vascular permeability and 
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swelling of the gland (edematous or interstitial pancreatitis). Vascular 
injury could lead to local microcirculatory failure and amplification of the 
pancreatic injury. (19,37) 
 There is also speculation about the role of ischemia- reperfusion 
injury in the pancreas. Reperfusion of damaged tissues leads to the 
release of free radicals and inflammatory cytokines into the circulation, 
which could cause further injury.(37) The importance of microcirculatory 
injury can be appreciated by the importance of aggressive fluid 
replacement in the management of acute pancreatitis, which minimizes 
this injury.      
Release of inflammatory mediators 
 Microscopic and radionuclide studies using Indium – 111 tagged 
leukocytes show marked glandular invasion by macrophages and 
polymorphonuclear leukocytes in early stages of animal and human 
pancreatitis. Activation of complement and the subsequent release of C5a 
have a significant role in the recruitment of these inflammatory cells. 
 Granulocyte and macrophage activation causes the release of 
proinflammatory cytokines  (tumor necrosis factor, interleukins 1,6 and 
8), arachidonic acid metabolites (prostaglandins, platelet-activating 
factor, and leukotrienes), proteolytic and lipolytic enzymes, and reactive 
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oxygen metabolites which overwhelm the scavenging capacity of 
endogenous antioxidant systems. These substances also interact with the 
pancreatic microcirculation to increase vascular permeability and induce 
thrombosis and hemorrhage, leading to pancreatic necrosis. 
 Activated pancreatic enzymes, microcirculatory impairment, and 
the release of inflammatory mediators lead to rapid worsening of 
pancreatic damage and necrosis. This interaction makes it difficult to 
estimate the individual roles of these factors in inducing pancreatic 
damage. In addition, approximately 80 percent with pancreatitis develop 
only interstitial pancreatitis rather than necrotizing pancreatitis; the 
factors involved in limiting the pancreatic damage are not well 
understood 
Complications 
Pancreatitis can cause serious complications, including: 
Pancreatic pseudocysts are common sequelae of acute pancreatitis or 
chronic pancreatitis, and the most common cystic lesion of the pancreas. 
They are important both in terms of management and differentiation from 
other cystic processes or masses in this region. 
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Terminology 
The following are the latest terms according to the updated Atlanta 
classification to describe fluid collections associated with acute 
pancreatitis 10,11: 
 fluid collections in interstitial oedematous pancreatitis 
o acute peripancreatic fluid collections (APFC): in the first 4 weeks: 
non-encapsulated peripancreatic fluid collections 
o pseudocysts: develop after 4 weeks; encapsulated peripancreatic or 
remote fluid collections 
 fluid collections in necrotising pancreatitis 
o acute necrotic collections (ANCs): in the first 4 weeks; non-
encapsulated heterogeneous non-liquefied material 
o walled-off necrosis (WON or WOPN): develop after 4 weeks; 
encapsulated heterogeneous non-liquefied material   
Clinical presentation 
Pancreatic pseudocysts are frequently found on imaging follow-up of 
pancreatitis, and may in themselves be asymptomatic for some time. 
Presentations attributable to a pseudocyst include: 
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 mass effect 
o biliary obstruction 
o gastric outlet obstruction 
 secondary infection 
Pathology 
Pseudocysts occur from disruption of pancreatic duct structure with 
resulting leakage and accumulation of pancreatic juice resulting in 
haemorrhagic fat necrosis. A severe inflammatory reaction that is incited 
by this results in encapsulation of the cyst by fibrous tissue. This usually 
takes 4-6 weeks. In approximately 50% of cases the cyst retains a 
communication with the pancreatic duct  Such cysts are more problematic 
to treat, and are more likely to recur. 
Aetiology 
 acute or chronic pancreatitis (most common) 
 pancreatic trauma 
 iatrogenic, e.g. post partial gastrectomy  
Radiographic features 
Pseudocysts are fluid filled oval or round collections with a 
relatively thick wall. They can be multiple and are most commonly 
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located in the pancreatic bed. However, they can be found anywhere from 
the groin to the mediastinum and even in the neck, having ascended in the 
retroperitoneum via the diaphragmatic hiatuses into the mediastinum 5.  
It is not possible to reliably distinguish infected from non-infected 
pseudocysts on imaging alone . 
Ultrasound 
Hypoechoic or anechoic collections with low-level echoes are often 
seen dependently representing debris. 
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CT 
Pseudocysts appear as well-circumscribed, usually round or oval 
peripancreatic fluid collections of homogeneously low attenuation, that 
are usually surrounded by a well-defined enhancing wall .  
According to the revised Atlanta classification, pseudocysts contain 
no non-liquefied components within the fluid collection . 
MRI 
 T1 
o hypo-intense (fluid signal) centre 
o wall demonstrates mild early enhancement, which progressively 
becomes more intense  
 T2 
o hyperintense (fluid signal) 
o layering or dependent debris, highly specific  
Treatment and prognosis 
Treatment of pseudocysts depends on size and presence of 
superimposed infection, as well as local mass effect (usually related to 
size). If the cysts are small (less than 4-6 cm) they mostly resolve 
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spontaneously. Approximately half of all pseudocysts resolve 
spontaneously . Indications for drainage include  
 infection 
 large size: > 4-6 cm 
 mass effect 
o gastric outlet obstruction 
o hydronephrosis 
o biliary obstruction 
 growth on serial scanning 
 Treatment options include: 
 open surgical debridement, or cystenterostomy with a Roux-en-Y 
jejunal loop  
 endoscopic drainage into the stomach (or duodenum)  
 percutaneous drainage 
o remains somewhat controversial, although increasingly accepted  
o many centres report high safety and efficacy  
o critics raise concern regarding potential reaccumulation and fistula 
formation to the skin (especially in patients with severe pancreatitis)  
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 Octreotide infusion: decreases amount of pancreatic secretions 
Cysts that do not communicate with the pancreatic duct usually do not 
recur, and are unlikely to create fistulae  
 Infection. Acute pancreatitis can make your pancreas vulnerable to 
bacteria and infection. Pancreatic infections are serious and require 
intensive treatment, such as surgery to remove the infected tissue. 
 Kidney failure. Acute pancreatitis may cause kidney failure, which 
can be treated with dialysis if the kidney failure is severe and 
persistent. 
 Breathing problems. Acute pancreatitis can cause chemical changes 
in your body that affect your lung function, causing the level of 
oxygen in your blood to fall to dangerously low levels. 
 Diabetes. Damage to insulin-producing cells in your pancreas from 
chronic pancreatitis can lead to diabetes, a disease that affects the way 
your body uses blood sugar. 
 Malnutrition. Both acute and chronic pancreatitis can cause your 
pancreas to produce fewer of the enzymes that are needed to break 
down and process nutrients from the food you eat. This can lead to 
malnutrition, diarrhea and weight loss, even though you may be 
eating the same foods or the same amount of food. 
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Pancreatic cancer. Long-standing inflammation in your pancreas caused 
by chronic pancreatitis is a risk factor for developing pancreatic cancer 
F. Management of Acute pancreatitis : 
Acute pancreatitis can be divided into two broad categories: 
1) Edematous or mild acute pancreatitis and 
2) Necrotizing or severe acute pancreatitis 
 
 Treatment of acute pancreatitis is based upon the severity of the 
condition, which is determined by the clinical, laboratory and a severity 
scoring system. Most attacks of acute pancreatitis are mild with recovery 
occurring within five to seven days. Death is unusual in such patients. In 
contrast, severe necrotizing pancreatitis is associated with a high rate of 
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complications and significant mortality. One study characterized an 
intermediate group called “moderately severe acute pancreatitis”, which 
comprised patients with local complications but no organ failure. (10) 
These patients had low mortality like mild acute pancreatitis but 
morbidity (requiring prolonged hospital stay and interventions) like 
severe acute pancreatitis. A subgroup of patients has early severe acute 
pancreatitis characterized by extended pancreatic necrosis with organ 
failure at admission called fulminant acute pancreatitis because of organ 
failure either at admission or within 72 hours (mortality 90 percent). (67) 
 Treatment of acute pancreatitis is aimed at correcting any 
underlying predisposing factors and at the pancreatic inflammation itself. 
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Supportive Care 
 The first step in managing patients with acute pancreatitis is 
determining whether the pancreatitis is likely to be mild or severe. 
 Mild acute pancreatitis is treated with supportive care including 
pain control, intravenous fluids, and correction of electrolyte and 
metabolic abnormalities. The majority of patients require no further 
therapy, and recover and eat within three to seven days. 
 In severe acute pancreatitis, intensive care unit monitoring and 
support of pulmonary, renal, circulatory, and hepatobiliary function may 
minimize systemic sequelae. (68) 
 Vital signs and urine output should be monitored every few hours 
in the first 24-48 hours. Patients with severe pancreatitis will need 
ongoing monitoring for other complications that might arise.  
 Fluid replacement is important because patients with necrotizing 
pancreatitis accumulate vast amounts of fluid in the injured pancreatic 
bed. Inadequate hydration can lead to hypotension and acute tubular 
necrosis. In addition, fluid depletion damages pancreatic microcirculation 
and results in pancreatic necrosis. At least one report suggested that 
inadequate fluid replacement (as evidenced by persistent 
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hemoconcentration at 24 hours) was associated with development of 
necrotizing pancreatitis. (69) 
 The exact amount and composition of fluid resuscitation that is 
required has not been extensively studied but several approaches have 
been published(70). Adequate fluid replacement can be assessed by 
improvement of vital signs and urine output and reduction in hematocrit 
and blood urea nitrogen over 24 hours, particularly if they were high at 
the onset. Monitoring the blood urea nitrogen may be particularly 
important, as both the BUN at the time of admission and the change in 
BUN during the first 24 hours of hospitalization predict mortality. 
Increased fluid resuscitation should be considered in patients whose BUN 
levels stay the same or increases. 
 Fluid should be titrated to maintain urine output of greater than 0.5 
cc/kg/hour. [71] A low urine output may already reflect the development of 
acute tubular necrosis rather than persistent volume depletion. In this 
setting, aggressive fluid replacement can lead to peripheral and 
pulmonary edema without improving the urine output. There is some 
evidence that fluid resuscitation with lactated Ringer’s solution may be 
superior to normal saline (72). 
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 Oxygen saturation needs to be assessed routinely and supplemental 
oxygen administrated to maintain arterial oxygen saturation of greater 
than 95 percent. 
 Deep vein thrombosis prophylaxis should be considered in 
bedridden patients. 
Pain Management  
 Abdominal pain is often the dominant symptom. Uncontrolled pain 
can contribute to the hemodynamic instability. Adequate pain control is 
mandatory.  Meperidine has been favored over morphine for analgesia in 
pancreatitis because studies showed that morphine caused an increase in 
sphincter of Oddipressure(73) . Fentanyl (intravenous) is being used 
increasingly for pain relief for all cases of mild AP due to its better safety 
profile, especially in renal impairment. 
Nutrition 
 Patients with mild pancreatitis can often be managed with 
intravenous hydration alone since recovery often occurs rapidly, allowing 
patients to resume an oral diet. Nutritional support is often required in 
patients with severe pancreatitis. 
 Nutritional support should be provided to those likely to remain 
fasting for more than seven days. Nasojejunal tube feeding (using an 
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elemental or semi-elemental formula) is preferred to total parenteral 
nutrition. 
Enteral 
 A benefit of early enteral nutrition is its ability to maintain the 
intestinal barrier. Bacterial translocation from the gut is probably a major 
cause of infection. 
 In a meta-analysis of eight trials, enteral nutrition significantly 
reduced mortality, multiple organ failure, systemic infections, and the 
need for surgery compared with those who received parenteral 
nutrition(74). Guidelines issued by the American College of 
Gastroenterology and the American Gastroenterological Association 
recommended enteral feeding for severe acute pancreatitis . 
 Radiologic or endoscopic placement of a jejunal feeding tube 
beyond the ligament of Treitz and enteral feeding should be attempted. If 
not possible, nasogastric feeding has been proposed as an easier 
alternative. A controlled trial comparing nasogastric with nasojejunal 
feedings found no significant differences in any of the clinical outcomes 
measured (75). 
 The presence of fluid collections or elevated pancreatic enzymes is 
not necessarily a contraindication to oral or enteral feeding. However, in 
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a subgroup of patients there is clear correlation of pain, recurrence of 
pancreatitis, or worsening of fluid collections to feeding, either oral or 
enteral. These patients often have disrupted pancreatic ducts with fluid 
collections. Drainage of fluid collections may allow resumption of oral 
intake. If the fluid collections are not considered suitable for drainage, 
total parenteral nutrition will be needed to maintain nutrition. If the target 
rate of enteral feeding is not achieved within 48 to 72 hours, 
supplemental parenteral nutrition should be provided. 
Parenteral 
 Parenteral nutrition should be initiated in patients who do not 
tolerate enteral feeding or in whom nutritional goals cannot be reached 
within two days. 
Control of Infection 
 The occurrence of pancreatic infection is a leading cause of 
morbidity and mortality in acute necrotizing pancreatitis. Approximately 
one-third of patients with pancreatic necrosis develop infected 
necrosis(11). Patients who develop infection tend to have more extensive 
necrosis. Although infection can occur early in the course of necrotizing 
pancreatitis, it is more often seen late in the clinical course (after 10 days) 
(76). 
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 The important organisms causing infection in necrotizing 
pancreatitis are predominantly gut-derived, including Escherichia coli, 
Pseudomonas, Klebsiella, and Enterococcus. The majority of infections 
(about 75 percent) are monomicrobial. Fungal infection and infection 
with gram-positive organisms are uncommon but occur more frequently 
in the setting of prophylactic antibiotic use for severe acute pancreatitis, 
especially when used for more than 10 to 14 days. Fungal infections 
occur in approximately 9 percent of necrotizing pancreatitis and it is not 
clear if they are associated with higher mortality. 
 Approaches taken to decrease bacterial infections in acute 
necrotizing pancreatitis include enteral feeding, systemic antibiotics, 
percutaneous computerized tomography (CT) guided aspiration, and 
necrosectomy. 
Role of Systemic antibiotics 
 The role of prophylactic systemic antibiotics in acute pancreatitis is 
unsettled since studies evaluating its benefits and harms(77) have produced 
contradictory results. Guidelines have been issued by multiple societies 
and differ in their recommendations 
 The American College of Gastroenterology guidelines do not 
recommend prophylactic antibiotics. 
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 Guidelines from the American Gastroenterological 
Association(153)  do not make a firm recommendation with regard to 
prophylactic antibiotics, but note that “Antibiotic prophylaxis, if used, 
should be restricted to patients with substantial pancreatic necrosis (>30 
percent of the gland necrotic by CT criteria) and should continue for no 
more than 14 days.” 
 Guidelines from the Italian Association for the Study of the 
Pancreas(79) recommend them for patients with CT-proven necrosis. 
Protease inhibitors  
 Protease inhibitors, a class of drugs used to treat or prevent 
infection by viruses, have been described in the treatment of acute 
pancreatitis in observational studies, but their role remains unclear (80). 
Percutaneous CT-guided aspiration 
 CT-guided percutaneous aspiration with gram’s stain and culture is 
recommended when infected pancreatic necrosis is suspected. Sterile 
necrosis does not usually require antibiotics and acute fluid collections do 
not require therapy in the absence of infection or obstruction of 
surrounding hollow viscous. 
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Necrosectomy 
 Surgical debridement of infected necrosis (necrosectomy) can be 
accomplished by open surgery or a minimally invasive approach 
(endoscopic or percutaneous radiologic). Indications for necrosectomy 
include a failure to improve after antibiotics and CT-guided aspiration or 
if the patient becomes unstable from pulmonary, cardiovascular, or renal 
complications. 
 Because of the high mortality and morbidity associated with early 
necrosectomy, patients may benefit from continued conservative 
management. (81,82) 
Treatment of Associated Conditions 
 In addition to the above treatment for pancreatic inflammation, 
treatment of acute pancreatitis is aimed at correcting any underlying 
predisposing factors, such as gallstones, hypertriglyceridemia, and 
complications of splenic vein thrombosis. 
Gallstone Pancreatitis 
  Gallstone pancreatitis requires specific therapeutics 
considerations. In this disorder, obstructive stones in the biliary tract or 
ampulla of Vater are responsible for the pancreatitis. 
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Endoscopic retrograde cholangiography 
 Early endoscopic retrograde cholangiography (ERCP) with 
papillotomy or surgical intervention to remove bile duct stones may 
lessen the severity of gallstone pancreatitis. Multiple studies suggest that 
early endoscopic papillotomy is of benefit in humans with acute biliary 
pancreatitis. 
 ERCP should be performed within 24 hours if there is concomitant 
cholangitis. In general, ERCP should be performed within 72 hours in 
those with a high suspicion of persistent bile duct stones (ie, visible 
common bile duct stone on noninvasive imaging, persistently dilated 
common bile duct, and jaundice). 
 Early ERCP in those with predicted or actual severe gallstone 
pancreatitis in the absence of cholangitis or a high suspicion of a 
persistent common bile duct stone is controversial(83,84). 
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Cholecystectomy 
 Cholecystectomy should be performed after recovery in all patients 
with gallstone pancreatitis prior to hospital discharge. It is indicated only 
after an attack of acute pancreatitis since the incidence of pancreatitis 
from gallstones is only 3 to 7 percent. Failure to perform cholecystectomy 
is associated with a 25 to 30 percent risk of recurrent acute pancreatitis, 
cholecystitis, or cholangitis within 6 to 18 weeks. The risk is highest in 
patients who did not undergo asphincterotomy.  
 In patients who have had mild pancreatitis, cholecystectomy can 
usually be performed safely within seven days after recovery. On the 
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other hand, in patients who have had severe necrotizing pancreatitis, 
delaying cholecystectomy for at least three weeks may be reasonable 
because of an increased risk of infection. There is some controversy about 
cholecystectomy after sphincterotomy in elderly patients. 
 Pancreatitis occurring in patients with gallstones suggests that there 
has been migration of stones into the common bile duct. Thus, a 
cholangiogram and clearance of the common bile duct if stones present 
either before or during surgery is mandatory to prevent recurrence after 
cholecystectomy. If the clinical suspicion of common bile duct stones is 
high (eg, in those with persistent or worsening liver test abnormalities or 
cholangitis), a preoperative ERCP is the best test as there is a high 
likelihood that therapeutic intervention (sphincterotomy, stone extraction) 
will be required. On the other hand, if the suspicion of persistent common 
bile duct stone is low (eg, if liver test normalize), an intraoperative 
cholangiogram during cholecystectomy may be preferable to avoid the 
morbidity associated with ERCP. 
 Magnetic resonance cholangiopancreaticography and endoscopic 
ultrasound are other imaging options that can exclude common bile duct 
stones(85). A preoperative ERCP can then be performed only in those with 
stones or sludge in the common bile duct. 
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Splenic Vein Thrombosis 
 Splenic vein thrombosis is seen in up to 19 percent of patients(86). 
Treatment should focus on the underlying pancreatitis since the effective 
treatment may be associated with spontaneous resolution of the 
thrombosis. Anticoagulation may be needed if there is extension of the 
clot into the portal or superior mesenteric vein resulting in hepatic 
decompensation or compromise of bowel perfusion. However, this needs 
to be considered along with the theoretical possibility of hemorrhage into 
pancreatic necrosis or fluid collections. 
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Abdominal compartment syndrome 
 Patients with severe pancreatitis are at increased risk for 
intraabdominal hypertension and abdominal compartment syndrome. 
Factors that can contribute to abdominal compartment syndrome in 
patients with acute pancreatitis include tissue edema from aggressive 
fluid resuscitation, peripancreatic inflammation, ascites, and ileus(87). If 
abdominal compartment syndrome is confirmed, either percutaneous 
catheter-based or surgical decompression is indicated . 
Chronic pancreatitis 
Chronic pancreatitis is inflammation of the pancreas that does not 
heal or improve—it gets worse over time and leads to permanent 
damage. Chronic pancreatitis eventually impairs a patient’s ability to 
digest food and make pancreatic hormones 
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Pain Management 
Significant pain associated with chronic pancreatitis can seriously 
reduce a patient’s quality of life. It is important to treat chronic 
pancreatitis as soon as it is diagnosed because repeated episodes of 
inflammation can cause irreversible damage, and pain relief becomes 
much less effective. Pain relief can be achieved with medication, 
often using the World Health Organization’s 3-step ladder approach 
to pain relief: 
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1. Pain medication begins with nonopioids (like acetaminophen, 
ibuprofen, or both). 
2. If nonopioids do not relieve pain, mild opioids (like codeine) 
are given. 
3. If mild opioids do not relieve pain, strong opioids (like 
morphine) are given. 
Many patients with chronic pancreatitis receive antioxidants with 
their pain medicine, which has been shown to help with pain relief.3-
5 There are other options for pain relief, such as a celiac plexus block, 
which may provide another option for significant pain relief. The 
celiac plexus block is achieved via injection and prevents the nerves 
that travel from the pancreas from reporting pain signals back to the 
brain. 
If there is a narrowing of the pancreatic duct, placement of a plastic 
tube called a stent into the duct can be helpful in alleviating pain 
symptoms. 
Limited Role of Endoscopic Retrograde 
Cholangiopancreatography (ERCP) 
An ERCP test, in which a flexible endoscope is placed into the 
intestine and a catheter is used to inject dye into the pancreas, should 
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generally not be used in chronic pancreatitis, and it should never be 
used to diagnose chronic pancreatitis because injecting dye into the 
pancreas can cause pancreatitis.  
Surgery 
When medical therapy fails to provide relief to patients with chronic 
pancreatitis, surgical therapy may be an option. A lateral 
pancreaticojejunostomy (modified Puestow procedure) can result in 
pain relief in up to 80% of patients. 
Whipple Procedure 
Another surgical procedure, which can remove inflammation and 
masses on the head of the pancreas, is the classic Whipple procedure; 
however, this procedure does remove a lot of important tissue and can 
be associated with complications such as increased risk of death. 
When possible, modified Whipple procedures are performed to save 
more tissue compared to the classic Whipple procedure, and can be 
successful for pain relief and return to daily activity. To read more,  
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TPIAT 
For appropriately selected patients whose pain remains incapacitating 
despite standard medical and surgical approaches, total 
pancreatectomy with islet auto-transplantation (TP-IAT) – while not a 
panacea – yields significant relief of symptoms.  
Antioxidant therapies 
Basic and clinical evidence suggests that the development of both 
acute pancreatitis (AP) and chronic pancreatitis (CP) can be 
associated with oxidative stress. Findings show that free radical 
activity and oxidative stress indices are higher in the blood and 
duodenal juice of patients with pancreatitis. 
Based on these findings, the idea of using antioxidant regimens in the 
management of both AP and CP as a supplement and complementary 
in combination with its traditional therapy is reasonable. In practice, 
however, the overall effectiveness of antioxidants is not known, and 
the best mixture of agents and dosages is not clear. Currently, a trial 
of a mixture of antioxidants containing vitamin C, vitamin E, 
selenium, and methionine is reasonable as one component of overall 
medical management. 
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In summation, there is no definite consensus on the dosage, length of 
therapy, and ultimately, the benefits of antioxidant therapy in the 
management of AP or CP. Further well-designed clinical studies are 
needed to determine the appropriate combination of agents, time of 
initiation, and duration of therapy.  
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MATERIALS AND METHODS 
 
 DESIGN OF STUDY: Randomized prospective comparative 
clinical study. 
 
Minimum of 100 consecutive patient diagnosed with acute pancreatitis of 
72 hrs or less duration 
INCLUSION CRITERIA: 
Patients diagnosed with acute pancreatitis based on the following 2 
criteria: 
1. Abdominal pain characteristic of acute pancreatitis (duration <72 
hrs) 
2. Serum  amylase and/or lipase ≥ 3times the upper limit of normal 
 
EXCLUSION CRITERIA: Patients 
1. Sensitive to LMWH 
2. Pregnant 
3. Breast feeding 
4. Coagulation disorders 
5. Undergoing haemodialysis 
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SOURCE OF DATA 
 patients admitted in COIMBATORE MEDICAL COLLEGE from 
june 2016 to august 2017 
 
METHODS OF DATA COLLECTION 
 
 Patients who satisfy the inclusion criteria will be enrolled into the 
study. Prior informed consent will be taken from the patients and relatives 
before enrolling them into the study. The particulars of the patient 
including name, age, gender, admitting diagnosis will be documented. 
 
 Patients will be assigned to 2 groups as random number table A 
and B.  
 
GROUP A patients  
 will undergo conventional therapy that includes management of 
shock ,maintenance of water and electrolytes balance, fasting, 
gastrointestinal  decompression , administration of pancreatic enzymes 
inhibitor(octreotide) , antibiotics (cephalosporins  and metronidazole) and 
oral manganese sulfate and symptomatic treatment. 
 
GROUP B patients: 
  The treatment included following the methods used in GROUP A 
patients, plus administering LMWH at 100 micro gram /kg per day 
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subcutaneous injection starting from the admission day and continuing 
for 7 days.  
OBSERVATION PARAMETERS 
 
Clinical parameters: Clinical Severity by Atlanta Criteria(Complication 
rate, occurrence rate of organ failure), in hospital mortality, curative rate 
and mean hospital stay in the two groups were observed and compared. 
Laboratory tests: 
            The APACHE II scores, parameters on admission and at 1 week 
after treatment were determined:  
STATISTICAL METHODS 
        Parametric and non parametric data will be analyzed using students 
t-test (paired and unpaired) and Chi- square test respectively. A P value<5 
will be considered significant. 
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RESULTS 
1. Comparison between groups 
In our study, there were 50 patients in the observation group (44 
men, 6 women; average age 40 years) and 50 patients in the control group 
(42 men, 8 women; average age 40.04 years). Differences in general data, 
such as sex and age, between the groups were not statistically significant 
(p > 0.05). Thus, the groups were comparable. 
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AGE DISTRIBUTION 
TABLE-1 
AGE(IN YRS) NO OF PATIENTS PERCENTAGE 
< 30 24 24% 
31-40 30 30% 
41-50 29 29% 
> 50 17 17% 
 
 
 
 
 
24%
30%
29%
17%
AGE DISTRIBUTION
< 30 31-40 41-50 > 50
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AGE IN YEARS 
TABLE-2 
  AGE IN YEARS 
TREATMENT MEAN SD 
WITH HEPARIN 40 9.44 
WITHOUT HEPARIN 40.04 11.92 
      
P VALUE - 0.985 
NON SIGNIFICANT 
UNPAIRED T TEST 
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40.04
39.9839.99
4040.01
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40.04
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MEAN AGE IN YRS
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AGE DISTRIBUTION AMONG GROUPS 
TABLE-3 
  TREATMENT 
AGE(IN YRS) WITH HEPARIN WITHOUT HEPARIN 
< 30 11 13 
31-40 14 16 
41-50 16 13 
> 50 9 8 
      
P VALUE - 0.880 
NON SIGNIFICANT 
KRUSKAL WALLIS TEST 
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SEX DISTRIBUTION 
TABLE-4 
SEX NO OF PATIENTS PERCENTAGE 
MALE 86 86% 
FEMALE 14 14% 
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SEX DISTRIBUTION AMONG GROUPS 
TABLE-5 
 TREATMENT 
SEX WITH HEPARIN WITHOUT HEPARIN 
MALE 44 42 
FEMALE 6 8 
   
P VALUE - 0.564 
NON SIGNIFICANT 
MANN WHITNEY U TEST 
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2. Changes in final outcome after treatment 
In our study out of 100 patients 96 patients recovered and 4 patients died. 
All the 4 patients were from control group. The final outcome of recovery 
rate between the two grops were statistically significant with (p <0.05), 
(Table 7) 
FINAL OUTCOME 
TABLE-6 
FINAL OUTCOME NO OF PATIENTS PERCENTAGE 
RECOVERED 96 96% 
DIED 4 4% 
 
  
99  
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FINAL OUTCOME AMONG GROUPS 
TABLE-7 
 TREATMENT 
FINAL OUTCOME WITH HEPARIN WITHOUT HEPARIN 
RECOVERED 50 46 
DIED 0 4 
   
P VALUE - 0.041 
SIGNIFICANT 
CHI SQUARE TEST 
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3. Changes in APACHE scores after treatment 
The APACHE II scores at admission were not significantly different 
between the groups (p > 0.05), (Table 8). After 7 days of treatment, the 
APACHE II scores in the observation group (i.e. patients treated with 
heparin) were significantly lower than those in the control group with (p 
< 0.05), (Table 9).   
TABLE-8 
APACHE SCORE - ON ADMISSION 
 APACHE SCORE - ON ADMISSION 
TREATMENT MEAN SD 
WITH HEPARIN 12.56 5.85 
WITHOUT HEPARIN 12.58 6.83 
   
P VALUE - 0.987 
NON SIGNIFICANT 
UNPAIRED T TEST 
 
102  
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APACHE SCORE- ON DAY 7 
TABLE-9 
 APACHE SCORE- ON DAY 7 
TREATMENT MEAN SD 
WITH HEPARIN 5.22 3.79 
WITHOUT HEPARIN 7.96 4.65 
   
P VALUE - 0.002 
SIGNIFICANT 
UNPAIRED T TEST 
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TREATMENT 
TABLE-10 
 TREATMENT 
APACHE SCORE WITH HEPARIN WITHOUT HEPARIN 
ON ADMISSION 12.56 11.35 
ON DAY 7 5.22 7.96 
MEAN DIFFERENCE 7.34 3.39 
P VALUE -0.005 
SIGNIFICANT 
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4. Changes in duration of hospital stay 
In our study mean duration of hospital stay in patients treated with 
heparin was 9.14 days and in patients treated without heparin was 
11.46 days. Which were statistically significant between the two 
groups with (p<0.05), (Table 11). 
    TABLE-11 
  DAYS IN HOSPITAL 
TREATMENT MEAN SD 
WITH HEPARIN 9.14 2.68 
WITHOUT HEPARIN 11.46 5.41 
      
P VALUE - 0.008 
SIGNIFICANT 
UNPAIRED T TEST 
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DISCUSSION 
 Although research on the pathogenesis and mechanisms of severe 
acute pancreatitis has progressed in recent years, the primary cause of the 
high mortality remains unknown. In early stages of pancreatitis, 
macrophages, neutrophils, endothelial cells are activated. 
Preinflammatory cytokines are released and inflammation factors re 
elevated during acute pancreatitis and have been implicated in 
progression of pancreatitis associated microvascular disturbance and 
hemorrhagic necrosis. Ischemia, reperfusion injury and tiny thrombosis 
are closely associated with pancreatic microcirculation disturbance1 
As an anticoagulation drug, LMWH can effectively restrain the 
activity of thrombin and blood coagulation factor Xa, inhibit platelet 
aggregation, and improve the microcirculation. LMWH can also reduce 
inflammation by lowering the expression of pro-inflammatory factors, 
inflammatory factors, adhesive factors. 
In this study, the curative effects of  adding lmwh alone in the 
treatment of  acute pancreatitis were compared with conventional 
strategy. The results showed obvious improvements in laboratory indices, 
much higher cure rate, and lower incidence of complications in the 
observation than in the control group, suggesting that LMWH safe and 
effective for treatment of severe acute pancreatitis.  
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Furthermore, the results showed that the decline in APACHE-II 
scores in the observation group was larger than that in the control group 
and lower values than those in C group (p < 0.05–0.01). The results of 
our study is on par with other international studies[5,6,7] 
APACHE-II scores show an obvious increase in the early stage (0 
– 48 h) and the increase becomes faster at 24 to 48 h. A continued 
increase in APACHE-II scores after discharge usually indicates disease 
progression. In this study, the APACHE-II scores in the observation 
group were much lower than those in the control group after treatment, 
suggesting that LMWH can relieve acute pancreatitis-related 
inflammation and reduce the incidence of complications. 
Limitations of the study 
This study found that LMWH had a marked effect in the treatment of 
acute pancreatitis. However, our study is a small, population based study 
from a single institution, from among patients admitted during a brief 
time-frame. Larger, multi institutional studies with larger sample size and 
longer time frames are needed to conform validity and accuracy my 
results. 
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 Patients were followed up till the time of discharge. Further follow 
up; to analyze further complications of acute pancreatitis did not fall 
under the parameters of our study. 
 Pediatric patients were not include in our study 
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CONCLUSION 
Findings From Our Study Found that use of LMWH in treatment of 
Acute pancreatitis, which acts by improving microcirculation is an 
effective drug in the non-surgical treatment of acute pancreatitis 
 As per our study, the APACHE II Scores reduced considerably in 
the group treated with LMWH, suggesting that there was a considerable 
improvement in laboratory values, higher cure rate and lower 
complication. Such as Necrosis, Abscess, sepsis and Organ failure 
etc.Thus LMWH can effectively relieve acute pancreatitis related 
inflammation and reduce incidence of complications 
 LMWH can rapidly relieve abdominal pain, halt the progression of 
diseases, reduce the severity and complication, shorten the length of 
hospital stay and enhance the cure rate 
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 PROFORMA 
 
PATIENT DATA COLLECTION FORM 
 
 
Patient NO: 
 
DEMOGRAPHIC DATA 
 Age:    Sex: 
 
 
1) APACHE-II 
  
The APACHE II Severity of Disease Classification System 
 HIGH ABNORMAL RANGE  LOW ABNORMAL RANGE 
Physiological 
variable +4 +3 +2 +1 0 +1 +2 +3 +4 
TEMPERATURE
 ( ° C ) 
> 41° 390- 40.8 °  
35.5° - 
38.9 ° 
36 ° - 
38.4 ° 
34 ° - 35.8 ° 32 ° - 33.9 ° 
30°- 
31.9 ° 
< 29.9 ° 
MEAN 
ARTERIAL 
PRESSURE (mm 
Hg) 
> 160 130 - 159 110-129  70 - 109  50-69  < 49 
HEART 
RATE (ventricular 
response) 
> 180 140 - 178 110-139  70 - 109  55-69 40-54 < 39 
 
RESPIRATORY 
RATE  
(non ventilated or 
ventilated) 
> 50 35 - 49  25-34 12 - 24 10-11 6 - 9  < 5 
 
OXYGENATION 
 
> 500 350 - 498 200 - 349  < 200 
PO, > 70 
200 - 349 
PO, 61 - 70 
200 - 349 
 
200 - 349 
PO, 55-60 
200 - 349 
PO, < 55 
ARTERIAL pH > 7.7 7.6 - 7.69  7.5 - 7.59 7.33 - 7.49  7.15 - 7.32 7.15 - 7.24 < 7.15 
 HIGH ABNORMAL RANGE   LOW ABNORMAL RANGE 
Physiological variable +4 +3 +2 +1 0 +1 +2 +3 +4 
         
 
SERUM 
SODIUM (meg/dl) 
> 180 160 - 179 155 - 159 150-  154 130 -   149  120 - 129 111 - 119 < 110 
SERUM 
POTASSIUM                  
     (meg/dl) 
> 7 6 - 6.9  5.5 -  5.9 3.5   - 5.4 3 - 3.4 2.5 - 2.9  < 2.5 
SERUM 
CREATININE                
    (mg/100 ml) 
> 3.5 2 - 3.4 1.3 - 1.9 0.6 - 1.4   < 0.6   
HEMATOCRIT (%) > 60   50 - 59.9 46 -  49.9 30 - 45.9  20-29.9  
< 20 
WHITE BLOOD 
COUNT (total/mm3) (in 
1000s) 
> 40   20 - 39.9 15 - 19.9 3 -   14.9  1-2.9  < 1 
 GLASGOW COMA 
SCORE (GCS) 
(score 15 minus actual 
GCS) 
                  
 
Total ACUTE 
PHYSIOLOGY 
SCORE(APS) 
Sum of the 12 individual 
variable points 
                  
SERUM HCO3 > 52 41 - 51.9   32 - 40.9 22 - 31.9   18 - 21.9 15 - 17.9 
< 15 
AGE POINTS 
 
Assign points to age as 
follows: 
 
  
  
  
  
 
CHRONIC HEALTH 
POINTS 
 
If the patient has a history 
of severe organ system 
AGE (yrs) POINTS 
< 44 0 
45 - 54 2 
55 - 64 3 
65 - 74 5 
> 75 6 
 
a. For nonoperative or 
emergency 
postoperative patients 
(5 points) 
 
b. for selective 
postoperative patients  
(2 points) 
 
 
DEFINITIONS: 
Organ insufficiency or 
immuno-compromised 
state must have been 
evident prior to the 
hospital admission and 
conform to the 
following criteria. 
 
 
 
 
LIVER: 
Biopsy proven 
cirrhosis and 
documented portal 
hypertension episodes 
 
RESPIRAT
ORY: 
Chronic 
restrictive, 
obstructive, 
or vascular 
disease 
resulting in 
severe 
exercise 
restriction. 
 
Unable to 
climb stairs 
or perform 
household 
duties: or 
documented 
chronic 
hypoxia, 
hypercapnia, 
secondary 
polycythemia
, severe 
pulmonary 
hypertension 
( > 
deficiency or is immuno - 
compromised, assign 
points as follows: 
of past upper GI 
bleeding attributed to 
portal hypertension:  
prior episodes of 
hepatic 
failure/encephalopathy
/coma. 
40mmHg), or 
respirator 
dependency. 
 
 
RENAL: 
Recurring 
chronic 
dialysis 
 
IMMUNO-
COMPROMI
SED: 
The patient 
has received 
therapy that 
suppresses 
resistance to 
infection [e.g. 
immuno-
suppression, 
chemotherapy
, radiation, 
long-term or 
recent high 
dose steroids] 
or has a 
disease that is 
sufficiently 
advanced to 
suppress 
resistance to 
infection [e.g. 
leukemia, 
lymphoma, 
AIDS] 
 
 
APACHE SCORE [ sum of A+B+C ] 
 
A. APS points 
 
B. Age points 
 
C. Chronic health points 
 
 
TOTAL APACHE SCORE 
 
 
CONSENT FORM 
PART 1 0F 2 
 
Dear volunteers,  
We welcome you and thank you for your interest in participation in this 
research project. Before you participate in this study , it is important for 
you to understand why this research is beign carried out.this form wil 
explain you all the relevant details of this research . it will explain the 
nature,the purpose,the benefits,the risks, the discomforts,the precautions 
and the information about how this project will be carried out. It is 
important that you read and understand the contentsof the form carefully. 
 
TITLE OF THE PROJECT:  “THE ROLE OF LOW MOLECULAR 
WEIGHT HEPARIN IN TREATMENT OF ACUTE PANCREATITIS 
Name of the investigator: 
What is the purpose of this project/study? 
To establish the use of low molecular weight heparin in treatment of 
acute pancreatitis 
 
How the study will be carried out? 
All patients of acute pancreatitis who the fit inclusion criteria will be 
included in study. For this research only data will be collected and no 
intervention will be done. 
 Following datas will be collected: 
Demographics (age,gender) 
 Etiology 
 Blood investigations 
a) Complete blood count 
b) Blood urea and creatinine 
c) Serum electrolytes 
d) Vitals monitoring 
 Clinical and severity scores  
Following is the Inclusion criteria: All patients admitted with the 
diagnosis of Acute Pancreatitis based on the presence of at least two of 
the following three criteria: 
1. Characteristic epigastric abdominal pain , with or without radiation 
to the back. 
2. Serum amylase or lipase levels elevated to at least three times the 
upper limit of normal. 
3. Characteristic finding of Acute Pancreatitis on abdominal CT scan. 
What is the expected duration of the subject participation? 
No additional stay in hospital is required than the usual course. 
What are the benefits to be expected from the research to the 
participant or to others and the post-trial responsibilities of the 
investigator? 
At the end of study we will be able to find the use of  LMW Heparin in 
treatment of acute pancreatitis. 
What are the risk factors expected from the study  to the 
participants? 
No risk as this is only an analytical study. 
Whether my participation in the study will be kept confidential ? 
Yes,confidentiality of records will be maintained. 
Is there provision of free treatment for research related injury? 
No intervention will be done for research purpose. So no research related 
injury is expected. 
 
 
Can I withdraw from study when I want? 
Yes. You can withdraw at any time without giving reason and this 
decicsion will not affect your regular medical care. 
 
PARTICIPANT  CONSENT FORM  
PART 2 OF 2 
Participants name:                                                             Address: 
 
Title of the project: 
“THE ROLE OF LOW MOLECULAR WEIGHT HEPARIN IN 
TREATMENT OF ACUTE PANCREATITIS 
The details of the study have been provided to me in writing and 
explained to me in my own language. I confirm that I have understood the 
above study and had the opportunity to ask questions. I understand that 
my participation in the study is voluntary and that I am free to withdraw 
at any time, without giving any reason, without the medical care that will  
normally be provided by the hospital being affected. I agree not to restrict 
the use of any data or results that arise from this study provided such a 
use is only for scientific purpose. I have been given information sheet 
giving details of the study. I fully consent to participate in the above 
study. 
I also consent /do not consent to use my stored biological samples for 
future scientific purposes –if applicable 
Signature of the participant:      Date: 
 
Signature of the witness:       Date 
 
Signature of the investigator:      Date:  
  
KEY TO MASTER CHART 
 
TPR   : TEMPERATURE ( ° C ) 
MAP   : MEAN ARTERIAL PRESSURE (mm Hg) 
HR   : HEART RATE (ventricular response) 
RR   : RESPIRATORY RATE  
    (non ventilated or ventilated) 
Na+   : SERUM SODIUM (meg/dl) 
K+   : SERUM POTASSIUM   (meg/dl) 
Creat   : SERUM CREATININE  (mg/100 ml) 
Hct   : HEMATOCRIT (%) 
WBC   : WHITE BLOOD COUNT (total/mm3) (in 1000s) 
GCS   : GLASGOW COMA SCORE (GCS) 
    (score 15 minus actual GCS) 
Total ACUTE PHYSIOLOGY SCORE(APS) 
Sum of the 12 individual variable points 
CHP     : Chronic Health Points 
 
NAME ` TPR (°C) MAP HR RR NA+ K+ CREAT HCT WBC GCS CHP Total Score
SUBBIAH 0 38.6 102 86 18 138 3.2(1) 1.6(1) 25.8(1) 7.8 0 0 3
SEKAR 0 38.5(1) 98 96 25(1) 142(1) 3.5 1.2 38.7 8.6 0 0 4
NAGARAJAN 0 37.6 108 92 28(1) 152(1) 3.8 1.3 26.5(1) 17.1(1) 0 0 4
KAREEM 0 38.8 84 90 20 139 3.7 0.8 39.2 8.2 0 0 1
PALANISAMY 1 39.6(2) 113(1) 96 15 154(1) 3.1(1) 1.8(1) 26.8(1) 22.5(2) 0 0 10
FAIZAL 0 39(1) 115(1) 116(1) 26(1) 142 3.3(1) 1.2 29.2(1) 16.8(1) 1 0 8
SHANTHAMANI 2 38.5 82 91 18 136 3.9 0.7 39.5 7.8 0 0 2
KRISHNAN 1 37.2 116(1) 94 18 142 3.2(1) 1.3 28.2(1) 18.1(1) 0 0 4
SHANMUGASUNDARAM 3 37 95 92 22 152(1) 4.1 1.6 39.1 9.2 0 0 5
BALAJI 0 37.6 96 82 16 140 3.8 1.3 27.8(2) 18.4(1) 0 0 3
VELUSAMY 2 38.6 108(1) 98 22 144 3.8 1.7(1) 29.1(1) 19.5(1) 0 0 7
GUNASEKARAN 0 38.5(1) 126(2) 128(2) 28(1) 1328 2.8(2) 0.8 30.2(1) 20.2(1) 1 0 11
ARULDAS 0 38.3 92 86 17 152(1) 3.9 1.2 36.3 16.7(1) 0 0 2
KARUPPUSAMY 0 38.8(1) 86 117(1) 27(1) 142 3.8 1.1 28.7(1) 24.2(2) 0 0 8
SUBBULAKSHMI 2 38.4 88 118(1) 26(1) 139 4 0.9 36.8 18.9(1) 0 0 5
ALAGIRI 2 36.8 80 110(2) 22 154(1) 5 2.5(2) 46.1 14.5 1 0 9
MANIKANDAN 2 36 110(2) 120(2) 30(2) 120(2) 5.5(1) 1.5(2) 45.9 4 1 0 14
JEBAKUMAR 0 37 100 110(1) 22 150(1) 3.5 1 25.5(2) 14.8 0 0 4
JOSEOH 0 36.8 82 98 18 150(1) 5 0.9 30.1 8 0 0 1
RAVICHANDRAN 2 38.5(1) 120(2) 102(2) 30(1) 150(1) 5.5(1) 1.6(2) 25(2) 18.6(1) 1 0 16
RADHAKRISHNAN 2 37 80 90 18 145 3.8 1 38 7 1 0 2
VIDYALAKSHMI 0 37 86 120(2) 18 136 2.4(2) 1.1 26.5(1) 14.1(1) 0 0 7
MANIVEL 2 36.7 80 120(2) 18 138 3.5 1 32 14 0 0 7
PRABHU 2 38 110(2) 100 22 136 3.8 2.6(2) 30.2 12 0 0 6
NARASIMMAN 2 36.2 80 70 12 155(2) 2.9(2) 1.2 50 15 2 0 10
DHANDAPANI 2 38.4 120(2) 120(2) 30(1) 150(1) 3.4(1) 1.3 46.1 20.1(2) 2 0 13
MILTON 0 37 112(2) 80 22 144 4.8 1.2 46(1) 16.6(1) 0 0 5
ESWARAN 0 36.7 90 78 16 152(1) 4.5 0.8 44.2 9 1 0 2
RAFEEQ 0 38.4(1) 110(2) 110(2) 22 158(1) 3.6 1.2 36 12 0 0 6
SELLAYA 0 38 88 90 22 145 5.6(1) 1.2 40 14 0 0 1
JAYARAMAN 0 37.2 80 82 18 132 4 1.2 42 8 1 0 1
BANUPRIYA 0 37.2 90 90 18 153(1) 3.5 1.5(1) 25(2) 12 0 0 4
PANDI 2 38 100 22 150 3.4(1) 1.6(2) 46(1) 15.1(1) 2 0 0 9
APACHE SCORE AT DAY 7
KALIYAMOORTHY 2 38 116(1) 125(2) 25(1) 138 4.1 1 36.5 14.2 0 0 6
DINESH 2 38.8(1) 113(1) 122(1) 28(1) 142 3.9 1.2 20.9(1) 15.4(1) 0 0 9
GANESAN 0 38.1 90 88 18 152(1) 3.8 0.8 37.2 8.2 0 0 1
CHANDRAN 0 38.1(1) 115(1) 123(2) 17 140 4.2 1.3 23.2(1) 7.3 1 0 6
VENKATESH 1 38.5 84 78 20 141 3.9 0.6 37.5 8.2 0 0 0
KANAGARAJ 2 37.3 115(1) 118(1) 22 141 3.9 1.2 39.2 15.5(1) 1 0 6
SENNIYAPPAN 2 33.8(2) 124(2) 128(2) 28(1) 128(1) 3.2(1) 1.9(1) 25.5(1) 14.8(1) 1 0 16
CHINNAKANNU 0 39.2(2) 92 126(2) 18 145 4.2 1 23.2(1) 12.5 0 0 5
SAMPATH 0 34.2(1) 90 65(1) 11(1) 151(1) 3.9 0.8 26.5(1) 18.7(1) 0 0 6
VASUMATHI 0 38.4 94 88 20 139 4.4 1.1 38.5 17.1(1) 0 0 1
ARUMUGAM 0 38.8(1) 116(2) 112(2) 28(1) 154(1) 3.1(1) 1.8(1) 20.6(1) 18.2(1) 0 0 11
PERIYASAMI 0 38.4 88 112(1) 18 152(1) 4.3 1.3 37.6 22.2(2) 0 0 4
MUNIYAPPAN 1 34(1) 36(1) 68(1) 10(1) 146 4.2 1.1 24.5(1) 18.4(1) 1 0 9
RAVIKUMAR 1 38.2 90 84 15 151(1) 3.8 0.9 32.5 10.5 0 0 2
PADMANABAN 0 38.4 92 78 16 153(1) 4.1 0.7 35.9 13.5 1 0 2
SHAKILA 2 36 92 70 14 138 3.8 1.2 32 9 0 0 2
RAJU 0 37.2 108 90 22 150(1) 3.4(1) 1.5(2) 35 7.2 0 0 4
UDHAYAKUMAR 1 37.4 106 94 25 156(1) 5.6(1) 1.6(2) 35 13.6 0 0 5
GOWRISHANKAR 1 38 100 112(2) 23 151 4.9 1.3 40 17(1) 2 0 6
BALAJI 2 38.6(1) 113(2) 105 26(1) 139 3.2(1) 1 40 15.5 0 0 7
VIJAYARUN 3 38.2 116(2) 115(2) 29(1) 145 3.6 1.1 38 15.3 1 0 9
GANAPATHY 0 38.2 118(2) 102(2) 25 140 3.2(1) 1.1 39 21(2) 0 0 7
ARULRAJ 0 38 110(2) 98 24 138 3.3(1) 1 37 17.1(1) 0 0 4
MADHU 2 38 112(2) 115(2) 30(1) 119(2) 3(1) 1.7(2) 34 18.1(1) 0 0 15
JOTHIMANI 3 37.6 128(2) 114(2) 32(1) 141 3.2(1) 1 27(2) 18.2(1) 0 0 12
NITHYA 1 38.2 105 106 20 140 5.6 1.7(2) 28.5 15.6 0 0 2
PRAKASH 1 38.8(1) 120(2) 115(2) 32(1) 136(1) 3.1(1) 1 28.5(2) 16.5(1) 1 0 13
RADHA 1 38.3 92 94 16 150(1) 4.6 1 40 13.5 0 0 2
SARAVANAKUMAR 1 38.6(1) 113(2) 124(2) 11(1) 150(1) 5.6(1) 1 36 15.2 1 0 10
SARATHA 0 37.4 90 106 11(1) 140 5.7(1) 1 46.5(1) 17 0 0 4
VELINGIRI 3 38.4(1) 116(2) 120(2) 32(1) 118(3) 3.2(1) 1.9(2) 40.2 1 0 0 18
NATRAJAN 2 38.8(1) 100 96 20 140 3.6 1.5(2) 28(2) 21(1) 0 0 8
SELVI 1 38.2 86 90 16 140 3.8 1 38 10.6 0 0 0
KALIMUTHU 1 38.5(1) 64(2) 67(2) 11(1) 140 3.2(1) 1 42 11 0 0 7
NAGAARAJ 1 38 104 106 26 136 4 1 46.1 12.2 0 0 2
MANOHARAN 0 38.6(1) 117(2) 114(2) 26(1) 155(2) 3.2(1) 1.7(2) 37 15.2 0 0 11
RAMASAMY 2 37.6 90 112(2) 20 138 2.9(2) 1.8(2) 27.8(2) 21.2(2) 0 0 12
SHIVA 3 37.8 113(2) 117(2) 20 148 3.9 1 37 11.6 0 0 7
GEETHA 1 38 117(2) 115(2) 20 140 3.2(1) 1.2 40.2(1) 20.1(2) 0 0 9
RAMESH 1 38.8(1) 116(2) 119(2) 30(1) 150(1) 5.6(1) 1.9(4) 19.8(4) 15.5 1 0 18
SHAHHER AHMED death
VALLI 0 37.6 86 90 18 140 4 1 4.2 11.6 0 0 0
RAMACHANDRAN 1 37.8 110(2) 112(2) 26(1) 140 4 1.1 28.8(1) 10.5 0 0 7
PARTHIBAN 0 38 90 116(2) 28(1) 129(2) 2.8(2) 1.1 1 17.4(1) 0 0 10
MAHALINGAM 1 38 112(2) 113(2) 26(1) 140 3.4(1) 1.1 28.9(2) 18.6(1) 1 0 11
PRADEEP 0 38.6(1) 112(2) 114(2) 27(1) 140 3.9 2.4(3) 29.2(2) 17.2(1) 0 0 12
GOPI 1 38 120(2) 116(2) 20 128(2) 3.2(1) 1.6(2) 46(1) 11.6 0 0 11
SHANKAR 0 38.8(1) 68(2) 69(2) 14 136 5.4 1 28.8(2) 11.6 0 0 7
SURESH 1 38.6(1) 112(2) 114(2) 26(1) 140 3.4(2) 1.1 40.1 21.1(2) 0 0 11
SUNDHAR RAJ 1 37.2 122(2) 112(2) 25(1) 152(1) 5.5(1) 1.5(2) 29.1(2) 15.6 0 0 12
JAMES ARUL RAJ 1 38 97 102 20 150(1) 2.4(4) 1.2 40 21.2(2) 0 0 9
SASI KUMAR 0 38 96 100 16 140 4 1 40.1 7.7 0 0 0
JAGADEESH 2 37.6 68(2) 69(2) 10(1) 160(3) 5.7(1) 1.8(2) 44.2(2) 18.6(1) 0 0 18
KUMAR 3 37.2 98 102 20 128(2) 3.2(3) 1 27.2 15.4 0 0 8
MOHAN 0 37.6 99 104 16 150(1) 3.3(1) 1.8(2) 28.8(1) 15.6 0 0 5
SHAKILA BANU 1 38.8(3) 117(2) 112(2) 25(1) 129(2) 3.2(1) 1.9(2) 28.6 21.1(1) 0 0 19
SELVA KUMAR death
KUMARASAMY 2 37.2 90 90 16 140 4 1.1 28.8(2) 15.2 0 0 2
SARAVANAN 0 38.5(1) 112(2) 114(2) 26(1) 128(1) 5.7(1) 3.8(2) 38.6 15.2 0 0 12
STEPHEN RAJ 0 38 96 102 20 152(1) 3.6 1.9(2) 28.7(2) 15.4 0 0 5
GOVINDHAMMAL 2 38 112(2) 116(2) 25(1) 140 3.3(1) 1 40.2 10.6 0 0 9
NARAYANASAMY 0 37.8 90 106 26(1) 152(1) 5.6(1) 1 29(2) 12.1 0 0 5
MARIMUTHU 1 37.2 97 90 14 126(2) 3.2(1) 1.2 28(2) 17.2(1) 0 0 7
LOGANATHAN 0 37.8 100 102 18 136 3.2(1) 1.7(2) 40 13 0 0 3
RAJAN death
SUNDARAM 1 37.6 98 104 22 153(1) 3.1(1) 1.7(2) 46.2(2) 11.6 0 0 6
THIRUMOORTHI 0 37.8 102 115(2) 25 140 2.7(2) 1.2 23.6(2) 21.2(2) 0 0 9
NAME AGE TPR (°C) MAP HR RR NA+ K+ CREAT HCT WBC GCS CHP Total Score
SUBBIAH 0 38.7 114 (2) 120 (2) 28 (1) 138 2.7 (2) 1.8 (2) 27.2 (2) 17.5 (1) 0 0 12
SEKAR 0 39. 2(2) 118 (2) 124 (2) 36 (3) 156 (2) 3.1 (1) 1.8 (2) 25.2 (1) 14.1 0 0 15
NAGARAJAN 0 37.2 112 (2) 118 (2) 26 (1) 160 (1) 3.9 1.5 36.6 20.1 (2) 1 0 9
KAREEM 0 38.2 94 118 (2) 20 128 (1) 3.1 (1) 1.8 (1) 25.8 (2) 15 0 0 7
PALANISAMY 1 39.1 (3) 126 (2) 130 (2)  10 (1) 142 5.6 (1) 2.8 (3) 29 (2) 26 (2) 1 0 18
FAIZAL 0 39.4 (2) 128(2) 138(2) 38(2) 154(2) 5.8(1) 2.2(2) 16.2(2) 25.4(2) 1 0 18
SHANTHAMANI 2 38 90 984 16 144 5.6(1) 0.7 24.8(2) 18(1) 0 0 6
KRISHNAN 1 36.9 98 126(2) 24(1) 124(1) 2.8(2) 1.2 26 16.2(1) 1 0 9
SHANMUGASUNDARAM 3 39.2 118(2) 128(2) 28(1) 127(2) 5.1(1) 3.2(2) 36.6(2) 16.2(1) 1 0 19
BALAJI 0 37.2 96 112(1) 14 152(2) 3.1(1 1.7(1) 26.6(2) 14.6 0 0 7
VELUSAMY 2 39 (3) 120(2) 110(2) 30(1) 136 3.2(1) 1.6 23.2(2) 25(2) 1 0 16
GUNASEKARAN 0 39.6 (3) 110(2) 130(3) 28(1) 138 2.7(2) 1.9(2) 27(2) 17.5(1) 1 0 17
ARULDAS 0 33.2 (2) 66(2) 70(2) 11 116(3) 2.6(3) 3.2(3) 24.3(2) 4 1 0 17
KARUPPUSAMY 0 38.1(1) 90 130(2) 36(3) 138 3.1(1) 1.2 22.7(2) 25.4(2) 1 0 12
SUBBULAKSHMI 0 37.1 110 120(1) 30(1) 138 1.6(2) 1.2 27(2) 28(2) 1 0 10
ALAGIRI 2 36.9 94 120(2) 22 164(3) 5 2.6(2) 40.1(1) 18(1) 2 0 13
MANIKANDAN 2 38.2 122(2) 126(2) 37(2) 126(2) 2.4(2) 2.3(2) 17(4) 22.5(2) 2 0 22
JEBAKUMAR 0 38 123(2) 130(2) 26(1) 157(2) 3.5 1 16.5(4) 16.8(1) 0 0 12
JOSEOH 0 37.1 84 120(2) 28(1) 152(1) 5.5(2) 0.9 26.5(1) 14.1(1) 0 0 8
RAVICHANDRAN 2 39.2(3) 126(2) 144(3) 36(2) 158(3) 5.5(1) 2.7(3) 18(4) 20.2(2) 2 0 27
RADHAKRISHNAN 2 38.7 90 98 12 145 3.8 0.9 36 7 0 0 2
VIDYALAKSHMI 0 38 90 135(2) 30(2) 136 2.9(3) 1.1 28.9(1) 17.2(1) 0 0 9
MANIVEL 2 36.8 96 128(2) 28(1) 129(2) 2.7(2) 0.8 26.2(1) 14.6(1) 1 0 12
PRABHU 2 39 (3) 120(2) 120(2) 30(1) 158(2) 5.8(1) 3.2(2) 20.1(1) 16.8(1) 0 0 17
NARASIMMAN 2 34 (1) 70 68(2) 9(2) 165(3) 2.6(2) 1.6(1) 46.2(1) 18.2(1) 2 0 19
DHANDAPANI 2 39.7 (3) 128(3) 136(2) 40(3) 166(3) 5.4(1) 2.0(3) 48.1(1) 41.2(4) 2 0 27
MILTON 0 39.6 (1) 119(2) 98 32(1) 144 2.4(4) 1.6(2) 18(2) 18.6(1) 1 0 14
ESWARAN 0 34.2(1) 94 68(2) 14 162(3) 4.2(1) 0.7 46.5(1) 7 2 0 10
RAFEEQ 0 40 (3) 124(2) 144(3) 39(2) 162(3) 2.6(2) 1.8(2) 25.5(1) 18.5(1) 0 0 19
SELLAYA 0 38 88 120(2) 30(1) 151(1) 6.5(2) 1 26.7(1) 16.3(1) 0 0 8
JAYARAMAN 0 38 125(2) 130(2) 26(1) 136 2.2(2) 1.2 25.8(1) 9 1 0 9
BANUPRIYA 0 37.5 92 162(2) 26(1) 158(2) 3.2(1) 1 16.9(2) 16.6(1) 0 0 9
PANDI 2 38.6 (1) 122 (2) 128(2) 38(2) 126(1) 2.8(2) 2.5(2) 17.0(2) 24.1(2) 2 0 20
APACHE SCORING AT THE TIME OF ADMISSION
KALIYAMOORTHY 2 38.4 110(1) 110(1) 28(1) 150(1) 4.6 1 26.0(2) 18.5(1) 1 0 10
DINESH 2 39 (3) 118(2) 120(2) 28(1) 127(2) 5.8(1) 3.2(2) 20.6(2) 16.8(1) 1 0 19
GANESAN 0 38 98 101(1) 16 152(1) 3.4(1) 1.7(1) 25.6(1) 17.2(1) 0 0 6
CHANDRAN 0 38.1 86 126(2) 30(1) 156(1) 6.4(3) 1.1 25.9(2) 10 1 0 11
VENKATESH 1 38 90 82 24(1) 145 3.8 1.2 36.5 16.2(1) 1 0 4
KANAGARAJ 1 38.1 116(1) 118(1) 30(1) 138 3.1(1) 1.2(2) 22.8 25.2(2) 1 0 10
SENNIYAPPAN 2 39.6 (4) 130(2) 140(3) 36(3) 160(3) 5.4 1.8(1) 18.4(2) 22.4(2) 1 0 23
CHINNAKANNU 0 36.8 94 96 32(1) 136 1.6(4) 1.2 27.6(2) 28(2) 1 0 10
SAMPATH 0 38 88 128(2) 29(1) 154(1) 6.5(3) 0.9 26.7(1) 16 1 0 9
VASUMATHI 0 37 98 110(1) 14 152(1) 3.2(1) 1.7(1) 24.8(1) 18.7(1) 0 0 6
ARUMUGAM 0 39 (2) 118(2) 130(2) 30(2) 163(3) 3.1(1) 3.2(2) 16.8(2) 26.2(3) 1 0 19
PERIYASAMI 0 38.6 82 116(1) 20 154(1) 4.6 1.2 26.8(2) 17(1) 0 0 5
MUNIYAPPAN 1 39.2(3) 120(2) 120(2) 30(1) 130(2) 2.1(4) 1.6(2) 25.8(2) 16.9(1) 0 0 20
RAVIKUMAR 1 38.06 110(1) 88 30(1) 152(1) 4.2 1.2 26.8(2) 11.5 0 0 6
PADMANABAN 0 33 (2) 65(2) 68(2) 12 136 5.4 1.2 25.5(2) 10.8 1 0 9
SHAKILA 2 36 90 72 14 138 3.1(1) 1.8(1) 25.8(1) 14 1 0 6
RAJU 0 38.6(1) 120(2) 120(2) 25(1) 152(2) 2.6(1) 2.4(2) 27.2(1) 15.8(1) 0 0 13
UDHAYAKUMAR 1 37 108 115(2) 26(1) 152(1) 5.8(1) 1.8(1) 47(1) 18(1) 0 0 9
GOWRISHANKAR 1 37.4 105 118(1) 25(1) 150(1) 5 1.7(1) 26(1) 22.2(2) 2 0 10
BALAJI 2 38.6(1) 116(1) 114(1) 28(1) 136 2.8(2) 1.1 24(1) 16(1) 0 0 10
VIJAYARUN 3 38.8(1) 102 126(2) 32(1) 158(2) 3.2(1) 1 21(1) 13 2 0 13
GANAPATHY 0 37.6 92 116(1) 30(1) 150(1) 2.6(2) 1.2 25(1) 24(2) 1 0 9
ARULRAJ 0 37.5 112(1) 128(2) 27(1) 135 3.2(1) 1.1 38 12 0 0 5
MADHU 2 38.8 115 118(1) 36(2) 118(2) 3.2(1) 1.8(2) 26(2) 24(2) 2 0 19
JOTHIMANI 3 37.2 95 116(1) 36(2) 140 2.6(2) 0.9 28(2) 26(2) 3 0 15
NITHYA 1 37.4 108 117(1) 26(1) 136 5.8(1) 1.8(1) 24.5(2) 16.1(1) 1 0 9
PRAKASH 1 38.7 (1) 129(2) 124(2) 36(2) 124(1) 3.2(1) 1.9(2) 28(2) 16.1(1) 2 0 17
RADHA 1 37.6 98 84 16 138 3.8 1.1 38 18(1) 2 0 4
SARAVANAKUMAR 1 33.8 (2) 114(1) 68(1) 10(1) 159(2) 5.8(1) 0.8 26(2) 16(1) 2 0 14
SARATHA 0 34.2(1) 62(1) 108 10(1) 142 5.6(1) 0.7 24.8(2) 18.5(1) 0 0 7
VELINGIRI 3 39.2(3) 124(2) 128(2) 36(3) 114(3) 3.0(1) 1.8(1) 28(2) 26.2(2) 2 0 24
NATRAJAN 2 34.6 (1) 90 88 18 124(2) 6.1(3) 1.6(1) 25.6(2) 28.6(2) 1 0 14
SELVI 1 37.6 78 82 14 136 3.6 1.6(1) 35.6 11 1 0 1
KALIMUTHU 1 35.4(1) 66(2) 68(2) 10(1) 138 3.1(1) 1.2(1) 24.6(2) 10.2 1 0 10
NAGAARAJ 1 38.6(1) 108 132(2) 25(1) 126(2) 3.8 0.7 27.2(2) 14.8 0 0 8
MANOHARAN 0 38.8(1) 118(2) 124(2) 36(3) 156(2) 3.1(1) 2.5(3) 25.6(2) 15.8(1) 0 0 15
RAMASAMY 2 37.2 88 117(2) 22 118(3) 2.7(2) 0.8 16.5(2) 26.5(2) 2 0 17
SHIVA 3 37.6 117(2) 118(2) 26(1) 112(1) 3.8 1.7(1) 36.6 16.4(1) 0 0 10
GEETHA 1 38.2 114(2) 128(2) 28(1) 138 2.6(2) 2.5(3) 27.2 17.5(1) 2 0 13
RAMESH 1 38.6 (1) 128(2) 138(2) 38(3) 158(2) 6.6(3) 1.8(1) 16.8(4) 18.2(1) 2 0 24
SHAHHER AHMED 3 39.6(2) 126(2) 134(2) 38(2) 162(3) 3.1(1) 3.2(1) 16.8(2) 26.2(2) 5 0 27
VALLI 0 37.2 82 88 16 138 3.8 1 38 16.5(1) 0 0 1
RAMACHANDRAN 1 38.6 (1) 112(1) 118(1) 28(1) 152(1) 4.6 1.2 26.8(2) 11.5 1 0 9
PARTHIBAN 0 38.1 86 132(2) 36(3) 128(2) 2.2(4) 1.1 25.8(2) 16.9(1) 0 0 16
MAHALINGAM 1 38.2 116(1) 118(1) 36(3) 138 3.1(1) 0.9 22.8(2) 25.4(2) 2 0 14
PRADEEP 0 39.4(3) 128(2) 126(2) 38(3) 142 3.8 3.2(3) 20.8(2) 16.8(1) 0 0 16
GOPI 1 37.6 86 132(2) 22 118(3) 2.6(2) 3.0(3) 24.3(2) 16.1(1) 0 0 14
SHANKAR 0 33.2 (2) 65(2) 68(2) 10(1) 132 5.5 0.9 25.5(2) 10.8 0 0 9
SURESH 1 39.1 (3) 118(3) 126(2) 32(1) 136 3.4(1) 1.2 23.2(2) 24.5(2) 1 0 15
SUNDHAR RAJ 1 36.9 115(2) 126(2) 29(1) 158(2) 6.5(2) 1.6(1) 28.6(2) 18.6(1) 2 0 17
JAMES ARUL RAJ 1 37.1 119(1) 116(1) 32(1) 138 1.6(4) 1.2 28(2) 28.0(2) 2 0 14
SASI KUMAR 0 38.7(1) 94 98 14 144 3.8 0.7 38 7 0 0 1
JAGADEESH 2 34.2(1) 68(1) 68(1) 8(2) 162(3) 5.8(1) 2.5(3) 46.5(1) 26.5(2) 3 0 23
KUMAR 3 36.9 94 128(2) 26(1) 124(1) 2.6(2) 0.8 26.2(1) 16.7(1) 1 0 12
MOHAN 0 37.2 98 116(1) 14 152(1) 3.2(1) 1.7(1) 25.8(1) 17.2(1) 0 0 6
SHAKILA BANU 1 38.7(1) 124(2) 128(2) 39(2) 128(1) 2.6(2) 2.5(3) 17.1(4) 24.5(2) 3 0 24
SELVA KUMAR 3 39.2(3( 126(2) 144(3) 38(2) 162(3) 5.6(1) 1.8(1) 18(2) 22.2(2) 5 0 30
KUMARASAMY 2 36.9 96 128(2) 14 156(2) 3.6 3.2(1) 20.8(2) 18.5(1) 0 0 5
SARAVANAN 0 39.9(3) 118(2) 84 28(1) 127(2) 5.8(1) 1 20.6(2) 16.8(1) 0 0 17
STEPHEN RAJ 0 37.5 92 117(1) 26(1) 158(2) 3.6 1.2 16.9(4) 16.8(1) 0 0 9
GOVINDHAMMAL 2 38.2 125(2) 132(2) 28(1) 136 2.8(2) 1.1 25.9(2) 10 2 0 13
NARAYANASAMY 0 38 86 129(2) 30(1) 158 6.5(3) 0.9 26.7(1) 16.1(1) 0 0 10
MARIMUTHU 1 35.2(1) 88 64(1) 12 132 2.8(2) 1.3 27.6(2) 18.9(1) 2 0 10
LOGANATHAN 0 38 98 116(1) 29(1) 128(1) 3.8(1) 1.8(1) 25.8(2) 14.2 0 0 7
RAJAN 3 39.4(2) 126(2) 138(2) 36(2) 156(2) 5.8(1) 2.1(2) 16.2(2) 25.2(2) 5 0 12
SUNDARAM 1 38.3 112(2) 136(1) 33(1) 152(1) 3.2(1) 1.6(1) 28.2(2) 10.5 2 0 26
THIRUMOORTHI 0 38 94 113(2) 26(1) 136 2.6(2) 1.9(4) 20.9(2) 24.5(2) 1 0 13
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SUBBIAH 29 1 MALE 3.6.16 10.6.16 7 12 8 RECOVERED 1 YES 1
SEKAR 32 2 MALE 3.6.16 10.6.16 7 15 4 RECOVERED 1 YES 1
NAGARAJAN 32 2 MALE 10.6.16 18.6.16 8 9 3 RECOVERED 1 YES 1
KAREEM 42 3 MALE 10.6.16 17.6.16 7 7 0 RECOVERED 1 YES 1
PALANISAMY 40 2 MALE 1.7.16 12.7.16 11 17 9 RECOVERED 1 YES 1
FAIZAL 43 3 MALE 8.7.16 20.7.16 12 18 8 RECOVERED 1 YES 1
SHANTHAMANI 46 3 FEMALE 22.7.16 29.7.16 7 6 2 RECOVERED 1 YES 1
KRISHNAN 41 3 MALE 29.7.16 6.8.16 7 9 4 RECOVERED 1 YES 1
SHANMUGASUNDARAM 57 4 MALE 5.8.16 14.8.16 9 19 5 RECOVERED 1 YES 1
BALAJI 29 1 MALE 12.8.16 19.8.16 7 7 2 RECOVERED 1 YES 1
VELUSAMY 50 3 MALE 26.8.16 8.9.16 13 16 7 RECOVERED 1 YES 1
GUNASEKARAN 33 2 MALE 2.9.16 14.9.16 12 11 11 RECOVERED 1 YES 1
ARULDAS 38 2 MALE 9.9.16 19.9.16 10 17 2 RECOVERED 1 YES 1
KARUPPUSAMY 53 4 MALE 23.9.16 30.9.16 7 12 6 RECOVERED 1 YES 1
SUBBULAKSHMI 43 3 FEMALE 30.9.16 7.10.16 7 10 3 RECOVERED 1 YES 1
ALAGIRI 53 4 MALE 27.1.17 6.2.17 10 13 9 RECOVERED 1 YES 1
MANIKANDAN 46 3 MALE 3.2.17 18.2.17 15 22 4 RECOVERED 1 YES 1
JEBAKUMAR 28 1 MALE 10.2.17 21.2.17 11 12 4 RECOVERED 1 YES 1
JOSEOH 30 1 MALE 17.2.17 25.2.17 7 8 1 RECOVERED 1 YES 1
RAVICHANDRAN 50 3 MALE 24.2.17 13.3.17 17 27 16 RECOVERED 1 YES 1
RADHAKRISHNAN 53 4 MALE 3.3.17 10.3.17 7 5 2 RECOVERED 1 YES 1
VIDYALAKSHMI 26 1 FEMALE 17.3.17 24.3.17 7 9 7 RECOVERED 1 YES 1
MANIVEL 52 4 MALE 24.3.17 1.4.17 8 12 5 RECOVERED 1 YES 1
PRABHU 42 3 MALE 7.4.17 17.4.17 10 17 6 RECOVERED 1 YES 1
NARASIMMAN 50 3 MALE 14.4.17 27.4.17 13 19 10 RECOVERED 1 YES 1
DHANDAPANI 51 4 MALE 21.4.17 5.5.17 14 27 13 RECOVERED 1 YES 1
MILTON 35 2 MALE 28.4.17 8.5.17 10 14 5 RECOVERED 1 YES 1
ESWARAN 38 2 MALE 5.5.17 13.5.17 8 10 2 RECOVERED 1 YES 1
RAFEEQ 19 1 MALE 12.5.17 21.5.17 9 19 6 RECOVERED 1 YES 1
SELLAYA 43 3 MALE 26.5.17 2.6.17 7 8 1 RECOVERED 1 YES 1
JAYARAMAN 45 3 MALE 2.6.17 9.6.17 7 9 1 RECOVERED 1 YES 1
BANUPRIYA 40 2 FEMALE 9.6.17 16.6.17 7 9 4 RECOVERED 1 YES 1
PANDI 52 4 MALE 23.6.17 3.7.17 10 20 9 RECOVERED 1 YES 1
KALIYAMOORTHY 52 4 MALE 7.10.16 16.10.16 9 10 6 RECOVERED 1 YES 1
DINESH 51 4 MALE 14.10.16 22.10.16 8 19 9 RECOVERED 1 YES 1
GANESAN 28 1 MALE 28.10.16 4.11.16 7 6 1 RECOVERED 1 YES 1
CHANDRAN 30 1 MALE 4.11.16 12.11.16 8 10 6 RECOVERED 1 YES 1
VENKATESH 36 2 MALE 18.11.16 25.11.16 7 4 0 RECOVERED 1 YES 1
KANAGARAJ 40 2 MALE 25.11.16 2.12.16 7 10 6 RECOVERED 1 YES 1
SENNIYAPPAN 48 3 MALE 2.12.16 16.12.16 14 23 15 RECOVERED 1 YES 1
CHINNAKANNU 24 1 MALE 2.12.16 12.12.16 10 10 5 RECOVERED 1 YES 1
SAMPATH 22 1 MALE 9.12.16 17.12.16 8 9 6 RECOVERED 1 YES 1
VASUMATHI 39 2 FEMALE 16.12.16 23.12.16 7 6 1 RECOVERED 1 YES 1
ARUMUGAM 41 3 MALE 23.12.16 7.1.17 15 19 11 RECOVERED 1 YES 1
PERIYASAMI 29 1 MALE 30.12.16 6.1.17 7 5 4 RECOVERED 1 YES 1
MUNIYAPPAN 34 2 MALE 30.12.16 11.1.17 12 19 3 RECOVERED 1 YES 1
RAVIKUMAR 36 2 MALE 6.1.17 13.1.17 7 5 1 RECOVERED 1 YES 1
PADMANABAN 39 2 MALE 6.1.17 13.1.17 7 9 2 RECOVERED 1 YES 1
SHAKILA 47 3 FEMALE 13.1.17 20.1.17 7 6 2 RECOVERED 1 YES 1
RAJU 43 3 MALE 20.1.17 29.1.17 9 13 4 RECOVERED 1 YES 1
UDHAYAKUMAR 30 1 MALE 1.6.16 9.6.16 8 9 5 RECOVERED 1 NO 2
GOWRISHANKAR 27 1 MALE 2.6.16 14.6.16 12 10 6 RECOVERED 1 NO 2
BALAJI 38 2 MALE 8.6.16 21.6.16 13 10 7 RECOVERED 1 NO 2
VIJAYARUN 59 4 MALE 16.6.16 1.7.16 15 13 9 RECOVERED 1 NO 2
GANAPATHY 38 2 MALE 28.6.16 7.7.16 9 9 7 RECOVERED 1 NO 2
ARULRAJ 40 2 MALE 1.7.16 9.7.16 8 5 4 RECOVERED 1 NO 2
MADHU 48 3 MALE 10.7.16 31.7.16 21 1 15 RECOVERED 1 NO 2
JOTHIMANI 56 4 MALE 24.7.16 13.8.16 25 15 12 RECOVERED 1 NO 2
NITHYA 24 1 FEMALE 3.8.16 13.8.16 10 9 5 RECOVERED 1 NO 2
PRAKASH 20 1 MALE 10.8.16 25.8.16 15 17 13 RECOVERED 1 NO 2
RADHA 42 3 FEMALE 20.8.6 27.8.16 7 4 2 RECOVERED 1 NO 2
SARAVANAKUMAR 36 2 MALE 30.8.16 9.9.16 10 14 10 RECOVERED 1 NO 2
SARATHA 41 3 FEMALE 4.9.16 12.9.16 8 7 4 RECOVERED 1 NO 2
VELINGIRI 60 4 MALE 10.9.16 2 24 DIED 2 NO 2
NATRAJAN 46 3 MALE 20.9.16 29.9.16 9 14 8 RECOVERED 1 NO 2
SELVI 40 2 FEMALE 14.3.17 21.3.17 7 1 0 RECOVERED 1 NO 2
KALIMUTHU 40 2 MALE 16.3.17 25.3.17 9 10 7 RECOVERED 1 NO 2
NAGAARAJ 43 3 MALE 6.4.17 16.4.17 10 8 2 RECOVERED 1 NO 2
MANOHARAN 22 1 MALE 10.4.17 25.4.17 15 15 11 RECOVERED 1 NO 2
RAMASAMY 49 3 MALE 14.4.17 2.5.17 18 17 12 RECOVERED 1 NO 2
SHIVA 58 4 MALE 29.4.17 13.5.17 14 10 7 RECOVERED 1 NO 2
GEETHA 36 2 FEMALE 5.5.17 17.5.17 17 13 9 RECOVERED 1 NO 2
RAMESH 44 3 MALE 10.5.17 30.5.17 20 24 18 RECOVERED 1 NO 2
SHAHHER AHMED 62 4 MALE 20.5.17 2 27 DIED 2 NO 2
VALLI 40 2 FEMALE 24.5.17 31.5.17 7 1 0 RECOVERED 1 NO 2
RAMACHANDRAN 17 1 MALE 2.6.17 10.6.17 8 9 7 RECOVERED 1 NO 2
PARTHIBAN 30 1 MALE 6.6.17 22.6.17 16 16 10 RECOVERED 1 NO 2
MAHALINGAM 39 2 MALE 10.6.17 25.6.17 15 14 11 RECOVERED 1 NO 2
PRADEEP 40 2 MALE 14.6.17 29.6.17 15 16 12 RECOVERED 1 NO 2
GOPI 43 3 MALE 20.6.17 3.7.17 13 14 11 RECOVERED 1 NO 2
SHANKAR 25 1 MALE 24.6.17 4.7.17 10 9 7 RECOVERED 1 NO 2
SURESH 28 1 MALE 26.6.17 12.6.17 16 15 11 RECOVERED 1 NO 2
SUNDHAR RAJ 27 1 MALE 25.9.16 9.10.16 15 17 12 RECOVERED 1 NO 2
JAMES ARUL RAJ 30 1 MALE 1.10.16 17.10.16 16 14 9 RECOVERED 1 NO 2
SASI KUMAR 20 1 MALE 10.10.16 17.10.16 7 1 0 RECOVERED 1 NO 2
JAGADEESH 46 3 MALE 2.11.16 24.11.16 22 23 18 RECOVERED 1 NO 2
KUMAR 59 4 MALE 10.11.16 19.11.16 9 12 8 RECOVERED 1 NO 2
MOHAN 34 2 MALE 20.11.16 28.11.16 8 6 5 RECOVERED 1 NO 2
SHAKILA BANU 47 3 FEMALE 27.11.16 17.12.16 20 24 19 RECOVERED 1 NO 2
SELVA KUMAR 63 4 MALE 1.12.16 2 30 DIED 2 NO 2
KUMARASAMY 33 2 MALE 5.12.16 12.12.16 7 5 2 RECOVERED 1 NO 2
SARAVANAN 50 3 MALE 20.12.16 9.1.17 20 17 12 RECOVERED 1 NO 2
STEPHEN RAJ 38 2 MALE 1.1.17 11.1.17 10 9 5 RECOVERED 1 NO 2
GOVINDHAMMAL 49 3 FEMALE 13.1.17 22.1.17 9 13 9 RECOVERED 1 NO 2
NARAYANASAMY 40 2 MALE 22.1.17 30.1.17 8 10 5 RECOVERED 1 NO 2
MARIMUTHU 42 3 MALE 1.2.17 9.2.17 8 10 2 RECOVERED 1 NO 2
LOGANATHAN 28 1 MALE 5.2.17 12.2.17 7 7 3 RECOVERED 1 NO 2
RAJAN 63 4 MALE 15.2.17 2 26 DIED 2 NO 2
SUNDARAM 34 2 MALE 21.2.17 2.3.17 9 12 6 RECOVERED 1 NO 2
THIRUMOORTHI 38 2 MALE 10.3.17 20.3.17 10 13 9 RECOVERED 1 NO 2
